



US012053607B2

(12) **United States Patent**
Ignon et al.

(10) **Patent No.:** **US 12,053,607 B2**

(45) **Date of Patent:** ***Aug. 6, 2024**

(54) **DEVICES AND METHODS FOR TREATING SKIN**

(71) Applicant: **HydraFacial LLC**, Long Beach, CA (US)

(72) Inventors: **Roger Ignon**, Redondo Beach, CA (US); **Scott Mallett**, Coto De Caza, CA (US); **Abraham Solano**, Corona, CA (US); **William Cohen**, Los Alamitos, CA (US)

(73) Assignee: **HydraFacial LLC**, Long Beach, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **18/487,916**

(22) Filed: **Oct. 16, 2023**

(65) **Prior Publication Data**

US 2024/0033491 A1 Feb. 1, 2024

Related U.S. Application Data

(63) Continuation of application No. 18/094,884, filed on Jan. 9, 2023, now Pat. No. 11,865,287, which is a (Continued)

(51) **Int. Cl.**

A61B 17/54 (2006.01)

A61B 17/3205 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61M 35/003** (2013.01); **A61B 17/3205** (2013.01); **A61B 17/50** (2013.01);

(Continued)

(58) **Field of Classification Search**

CPC ... A61B 17/3205; A61B 17/54; A61B 17/545; A61B 2017/00199; A61B 2017/00761;

(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

1,651,585 A 12/1927 Clair
D117,295 S 10/1939 Smith

(Continued)

FOREIGN PATENT DOCUMENTS

AT 400305 12/1995
AU 1014299 5/1999

(Continued)

OTHER PUBLICATIONS

Amazon.com: IeBilif Facial Skin Care Machine, posted Dec. 14, 2023 (retrieved online Mar. 29, 2024) from <https://www.amazon.com/IeBilif-Equipment-Esthetician-Essential-supplies/d> (2023).

(Continued)

Primary Examiner — Darwin P Erezzo

Assistant Examiner — Christian D Knauss


(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57)

ABSTRACT

An apparatus for treating skin has a console with a user input device and a handpiece assembly. The handpiece assembly is configured to treat skin. A fluid line provides fluid communication between the console and the handpiece assembly. A manifold system is coupled to the console and controlled by the user input device. The manifold system is configured to hold releasably a plurality of fluid sources and deliver fluid from at least one of the plurality of fluid sources to the handpiece assembly.

20 Claims, 25 Drawing Sheets



Related U.S. Application Data

- continuation of application No. 17/165,820, filed on Feb. 2, 2021, now Pat. No. 11,547,840, which is a continuation of application No. 16/517,268, filed on Jul. 19, 2019, now Pat. No. 11,446,477, which is a continuation of application No. 15/660,750, filed on Jul. 26, 2017, now Pat. No. 10,357,641, which is a continuation of application No. 14/700,789, filed on Apr. 30, 2015, now Pat. No. 9,814,868, which is a continuation of application No. 13/267,554, filed on Oct. 6, 2011, now Pat. No. 9,474,886, which is a continuation of application No. 11/392,348, filed on Mar. 29, 2006, now Pat. No. 8,048,089.
- (60) Provisional application No. 60/764,668, filed on Feb. 2, 2006, provisional application No. 60/755,310, filed on Dec. 30, 2005.
- (51) **Int. Cl.**
A61B 17/50 (2006.01)
A61B 50/10 (2016.01)
A61B 50/13 (2016.01)
A61M 1/00 (2006.01)
A61M 35/00 (2006.01)
A61M 37/00 (2006.01)
A61B 17/00 (2006.01)
A61B 17/32 (2006.01)
A61N 5/06 (2006.01)
- (52) **U.S. Cl.**
 CPC *A61B 17/54* (2013.01); *A61B 17/545* (2013.01); *A61B 50/10* (2016.02); *A61B 50/13* (2016.02); *A61M 1/962* (2021.05); *A61M 37/00* (2013.01); *A61B 2017/00199* (2013.01); *A61B 2017/00761* (2013.01); *A61B 2017/320004* (2013.01); *A61B 2217/005* (2013.01); *A61M 2037/0007* (2013.01); *A61N 5/0616* (2013.01)
- (58) **Field of Classification Search**
 CPC .. *A61B 2017/320004*; *A61B 2217/005*; *A61B 2217/007*; *A61M 1/774*; *A61M 35/003*
 See application file for complete search history.
- (56) **References Cited**
 U.S. PATENT DOCUMENTS
- | | | | |
|-----------|---|---------|------------------------|
| D151,807 | S | 11/1948 | Berkowitz |
| 2,608,032 | A | 8/1952 | Garver |
| 2,631,583 | A | 3/1953 | Lavergne |
| 2,701,559 | A | 2/1955 | Cooper |
| 2,712,823 | A | 7/1955 | Kurtin |
| 2,867,214 | A | 1/1959 | Wilson |
| 2,881,763 | A | 4/1959 | Robbins |
| 2,921,585 | A | 1/1960 | Schumann |
| 3,037,509 | A | 6/1962 | Schutz |
| 3,085,573 | A | 4/1963 | Meyer et al. |
| 3,214,869 | A | 11/1965 | Stryker |
| 3,468,079 | A | 9/1969 | Kaufman |
| 3,476,112 | A | 11/1969 | Elstein |
| 3,481,677 | A | 12/1969 | Abrahamson |
| 3,505,993 | A | 4/1970 | Lewes et al. |
| 3,560,100 | A | 2/1971 | Spatz |
| 3,574,239 | A | 4/1971 | Sollerud |
| 3,608,553 | A | 9/1971 | Balamuth |
| 3,715,838 | A | 2/1973 | Young et al. |
| 3,865,352 | A | 2/1975 | Nelson et al. |
| 3,866,264 | A | 2/1975 | Engquist |
| D237,776 | S | 11/1975 | Arassa et al. |
| D237,863 | S | 12/1975 | Peters et al. |
| 3,930,598 | A | 1/1976 | Slagle |
| 3,948,265 | A | 4/1976 | Al Ani |
| 3,964,212 | A | 6/1976 | Karden |
| 3,968,789 | A | 7/1976 | Simoncini |
| 3,977,084 | A | 8/1976 | Sloan |
| 4,121,388 | A | 10/1978 | Wilson |
| 4,155,721 | A | 5/1979 | Fletcher |
| 4,170,821 | A | 10/1979 | Booth |
| 4,182,329 | A | 1/1980 | Smit et al. |
| 4,203,431 | A | 5/1980 | Abura et al. |
| D255,325 | S | 6/1980 | Hoyt |
| 4,216,233 | A | 8/1980 | Stein |
| 4,225,254 | A | 9/1980 | Holberg et al. |
| D258,348 | S | 2/1981 | Hoyt |
| D259,921 | S | 7/1981 | Hartmann |
| D260,176 | S | 8/1981 | Boschetti et al. |
| 4,289,158 | A | 9/1981 | Nehring |
| 4,299,219 | A | 11/1981 | Norris, Jr. |
| 4,342,522 | A | 8/1982 | Mackles |
| 4,378,804 | A | 4/1983 | Cortese |
| 4,500,222 | A | 2/1985 | Clading-Boel |
| 4,560,373 | A | 12/1985 | Sugino et al. |
| D288,293 | S | 2/1987 | Arvans |
| 4,646,480 | A | 3/1987 | Williams |
| 4,646,482 | A | 3/1987 | Chitjian |
| 4,655,743 | A | 4/1987 | Hyde |
| 4,671,412 | A | 6/1987 | Gatten |
| 4,676,749 | A | 6/1987 | Mabille |
| D290,999 | S | 7/1987 | Novak |
| 4,706,676 | A | 11/1987 | Peck |
| 4,718,467 | A | 1/1988 | Di Gianfilippo et al. |
| 4,754,756 | A | 7/1988 | Shelanski |
| 4,757,814 | A | 7/1988 | Wang et al. |
| 4,764,362 | A | 8/1988 | Barchas |
| 4,795,421 | A | 1/1989 | Blasius, Jr. et al. |
| 4,811,734 | A | 3/1989 | McGurk-Burleson et al. |
| 4,836,192 | A | 6/1989 | Abbate |
| 4,866,202 | A | 9/1989 | Weil |
| 4,875,287 | A | 10/1989 | Creasy et al. |
| 4,886,078 | A | 12/1989 | Shiffman |
| 4,887,994 | A | 12/1989 | Bedford |
| 4,900,316 | A | 2/1990 | Yamamoto |
| 4,917,086 | A | 4/1990 | Feltoovich et al. |
| 4,925,450 | A | 5/1990 | Imonti et al. |
| D308,480 | S | 6/1990 | Hoyt |
| 4,940,350 | A | 7/1990 | Kim |
| 4,957,747 | A | 9/1990 | Stiefel |
| 4,990,841 | A | 2/1991 | Elder |
| 5,006,004 | A | 4/1991 | Dirksing et al. |
| 5,006,339 | A | 4/1991 | Bargery et al. |
| 5,012,797 | A | 5/1991 | Clarke |
| D317,719 | S | 6/1991 | Hestehave et al. |
| 5,035,089 | A | 7/1991 | Tillman et al. |
| 5,037,431 | A | 8/1991 | Summers et al. |
| 5,037,432 | A | 8/1991 | Molinari |
| 5,054,339 | A | 10/1991 | Yacowitz |
| 5,100,412 | A | 3/1992 | Rosso |
| 5,100,424 | A | 3/1992 | Jang |
| 5,119,839 | A | 6/1992 | Rudolph |
| 5,122,153 | A | 6/1992 | Harrel |
| 5,171,215 | A | 12/1992 | Flanagan |
| 5,192,269 | A | 3/1993 | Poli et al. |
| 5,207,234 | A | 5/1993 | Rosso |
| 5,217,455 | A | 6/1993 | Tan |
| 5,222,956 | A | 6/1993 | Waldron |
| 5,242,433 | A | 9/1993 | Smith et al. |
| 5,254,109 | A | 10/1993 | Smith et al. |
| 5,290,273 | A | 3/1994 | Tan |
| 5,368,581 | A | 11/1994 | Smith et al. |
| 5,387,215 | A | 2/1995 | Fisher |
| 5,391,151 | A | 2/1995 | Wilmot |
| 5,417,674 | A | 5/1995 | Smith et al. |
| 5,419,772 | A | 5/1995 | Teitz et al. |
| 5,423,803 | A | 6/1995 | Tankovich et al. |
| 5,437,372 | A | 8/1995 | Per-Lee |
| 5,441,490 | A | 8/1995 | Svedman |
| 5,460,620 | A | 10/1995 | Smith et al. |
| 5,470,323 | A | 11/1995 | Smith et al. |
| 5,484,427 | A | 1/1996 | Gibbons |
| 5,490,736 | A | 2/1996 | Haber et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

5,512,044	A	4/1996	Duer	6,176,198	B1	1/2001	Kao et al.
5,562,642	A	10/1996	Smith et al.	6,183,451	B1	2/2001	Mehl, Sr. et al.
5,562,643	A	10/1996	Johnson	6,183,483	B1	2/2001	Chang
5,611,687	A	3/1997	Wagner	6,190,376	B1	2/2001	Asah et al.
5,612,797	A	3/1997	Clarke	6,193,589	B1	2/2001	Khalaj
5,618,275	A	4/1997	Bock	6,196,982	B1	3/2001	Ball
5,626,631	A	5/1997	Eckhouse	6,231,593	B1	5/2001	Meserol
5,658,323	A	8/1997	Miller	6,235,039	B1	5/2001	Parkin et al.
5,658,583	A	8/1997	Zhang et al.	6,238,275	B1	5/2001	Metcalf et al.
5,674,235	A	10/1997	Parisi	6,241,739	B1	6/2001	Waldron
5,676,643	A	10/1997	Cann et al.	6,245,347	B1	6/2001	Zhang et al.
5,676,648	A	10/1997	Henley	6,264,666	B1	7/2001	Coleman et al.
5,683,971	A	11/1997	Rose et al.	6,269,271	B1	7/2001	Bernabei
5,697,920	A	12/1997	Gibbons	6,277,116	B1	8/2001	Utely et al.
5,707,383	A	1/1998	Bays	6,277,128	B1	8/2001	Muldner
5,713,785	A	2/1998	Nishio	6,280,438	B1	8/2001	Eckhouse et al.
5,735,833	A	4/1998	Olson	6,283,978	B1	9/2001	Cheski et al.
5,755,751	A	5/1998	Eckhouse	6,284,266	B1	9/2001	Zhang et al.
5,759,185	A	6/1998	Grinberg	6,299,620	B1	10/2001	Shadduck
5,762,640	A	6/1998	Kajiwaru et al.	6,306,119	B1	10/2001	Weber et al.
5,779,519	A	7/1998	Oliver	6,306,147	B1	10/2001	Bernabei et al.
5,800,446	A	9/1998	Banuchi	6,322,548	B1	11/2001	Payne et al.
5,807,353	A	9/1998	Schmitz	6,322,568	B1	11/2001	Bernabei et al.
5,810,842	A	9/1998	Di Fiore et al.	6,325,381	B1	12/2001	von Engelbrechten
5,813,416	A	9/1998	Rudolph	6,325,769	B1	12/2001	Klopotek
5,817,050	A	10/1998	Klein	6,332,886	B1	12/2001	Green et al.
5,817,089	A	10/1998	Tankovich et al.	6,334,074	B1	12/2001	Spertell
5,834,510	A	11/1998	Yu et al.	6,355,054	B1	3/2002	Neuberger
5,846,215	A	12/1998	Zygmunt	6,368,333	B2	4/2002	Bernabei et al.
5,848,998	A	12/1998	Marasco, Jr.	6,383,177	B1	5/2002	Balle-Petersen et al.
5,857,995	A	1/1999	Thomas et al.	6,387,089	B1	5/2002	Kreindel et al.
5,861,142	A	1/1999	Schick	6,387,103	B2	5/2002	Shadduck
5,873,881	A	2/1999	McEwen et al.	6,401,289	B1	6/2002	Herbert
5,879,323	A	3/1999	Henley	6,409,736	B1	6/2002	Bernabei
5,879,376	A	3/1999	Miller	6,410,599	B1	6/2002	Johnson
5,882,201	A	3/1999	Salem	RE37,796	E	7/2002	Henley
5,885,260	A	3/1999	Mehl, Sr. et al.	6,414,032	B1	7/2002	Johnson
5,908,401	A	6/1999	Henley	6,420,431	B1	7/2002	Johnson
5,911,223	A	6/1999	Weaver et al.	6,423,078	B1	7/2002	Bays et al.
5,919,152	A	7/1999	Zygmunt	6,423,750	B1	7/2002	Johnson
5,919,479	A	7/1999	Zhang et al.	6,432,113	B1	8/2002	Parkin et al.
5,954,730	A	9/1999	Bernabei	6,432,114	B1	8/2002	Rosso
5,971,999	A	10/1999	Naldoni	6,458,109	B1	10/2002	Henley et al.
5,980,555	A	11/1999	Barbut et al.	6,471,712	B2	10/2002	Burres
6,019,749	A	2/2000	Fields et al.	6,477,410	B1	11/2002	Henley et al.
6,023,639	A	2/2000	Hakky et al.	6,482,212	B1	11/2002	Bernabei et al.
6,024,733	A	2/2000	Eggers et al.	6,488,646	B1	12/2002	Zygmunt
6,027,402	A	2/2000	Oliver	6,494,856	B1	12/2002	Zygmunt
6,027,495	A	2/2000	Miller	6,500,183	B1	12/2002	Waldron
6,032,071	A	2/2000	Binder	6,503,256	B2	1/2003	Parkin et al.
6,036,684	A	3/2000	Tankovich et al.	6,508,813	B1	1/2003	Altshuler
6,039,745	A	3/2000	Di Fiore et al.	6,511,486	B2	1/2003	Mercier et al.
6,042,552	A	3/2000	Cornier	6,514,243	B1	2/2003	Eckhouse et al.
D425,241	S	5/2000	Nishizawa et al.	6,514,262	B1	2/2003	Di Fiore et al.
6,074,382	A	6/2000	Asah et al.	6,514,278	B1	2/2003	Hibst et al.
6,080,165	A	6/2000	DeJacma	6,518,538	B2	2/2003	Bernabei
6,080,166	A	6/2000	McEwen et al.	6,520,931	B2	2/2003	Suh
D428,142	S	7/2000	Stromblad	D472,136	S	3/2003	Hermann
6,090,085	A	7/2000	Mehl, Sr. et al.	6,527,716	B1	3/2003	Eppstein
6,093,021	A	7/2000	Rainey	6,527,783	B1	3/2003	Ignon
6,113,559	A	9/2000	Klopotek	6,533,776	B2	3/2003	Asah et al.
6,120,512	A	9/2000	Bernabei	6,535,761	B2	3/2003	Bernabei
6,129,701	A	10/2000	Cimino	6,537,242	B1	3/2003	Palmer
6,136,008	A	10/2000	Becker et al.	6,540,757	B1	4/2003	Hruska et al.
6,139,553	A	10/2000	Dotan	6,546,281	B1	4/2003	Zhang et al.
6,139,554	A	10/2000	Karkar et al.	6,562,013	B1	5/2003	Marasco, Jr.
6,142,155	A	11/2000	Rudolph	6,562,050	B1	5/2003	Owen
6,149,634	A	11/2000	Bernabei	6,564,093	B1	5/2003	Ostrow et al.
6,149,644	A	11/2000	Xie	6,565,535	B2	5/2003	Zaias et al.
6,159,226	A	12/2000	Kim	6,569,157	B1	5/2003	Shain et al.
6,162,218	A	12/2000	Elbrecht et al.	6,582,442	B2	6/2003	Simon et al.
6,162,232	A *	12/2000	Shadduck A61B 17/545	6,587,730	B2	7/2003	Bernabei
			604/289	6,589,218	B2	7/2003	Garcia
6,165,059	A	12/2000	Park et al.	6,592,595	B1	7/2003	Mallett et al.
6,174,325	B1	1/2001	Eckhouse	6,595,934	B1	7/2003	Hissong et al.
				6,611,706	B2	8/2003	Avrahami et al.
				6,626,445	B2	9/2003	Murphy et al.
				6,629,927	B1	10/2003	Mesaros et al.
				6,629,971	B2	10/2003	McDaniel

(56)

References Cited

U.S. PATENT DOCUMENTS

6,629,974 B2	10/2003	Penny et al.	D548,341 S	8/2007	Ohta et al.
6,629,983 B1	10/2003	Ignon	D548,843 S	8/2007	Kertz
6,635,035 B1	10/2003	Marasco et al.	D553,005 S	10/2007	Py et al.
6,641,591 B1	11/2003	Shaddock	7,276,051 B1	10/2007	Henley et al.
6,645,184 B1	11/2003	Zelickson et al.	7,293,930 B2	11/2007	Chuang
6,652,888 B2	11/2003	Rhoades	D557,611 S	12/2007	Ingemarsson
6,666,874 B2	12/2003	Heitzmann et al.	7,314,326 B2	1/2008	Rosenberg
6,673,081 B1	1/2004	Tavger et al.	7,316,657 B2	1/2008	Kleinhenz et al.
6,673,082 B2	1/2004	Mallett et al.	7,316,671 B2	1/2008	Lastovich et al.
D486,915 S	2/2004	Warschewske et al.	7,318,828 B1	1/2008	Revivo
6,685,853 B1	2/2004	Angelopoulos et al.	7,320,691 B2	1/2008	Pilcher et al.
6,687,537 B2	2/2004	Bernabei	7,320,801 B2	1/2008	Kelly
6,689,380 B1	2/2004	Marchitto et al.	7,326,199 B2	2/2008	MacFarland et al.
6,695,853 B2	2/2004	Karasiuk	7,329,252 B1	2/2008	Yamazaki et al.
6,699,237 B2	3/2004	Weber et al.	7,354,423 B2	4/2008	Zelickson et al.
6,712,805 B2	3/2004	Weimann	7,364,565 B2	4/2008	Freeman
6,726,673 B1	4/2004	Zhang et al.	D568,473 S	5/2008	Ashiwa et al.
D490,561 S	5/2004	Angeletta	7,367,981 B2	5/2008	Bernaz
6,735,470 B2	5/2004	Henley et al.	7,384,405 B2	6/2008	Rhoades
6,743,211 B1	6/2004	Prausnitz et al.	7,422,567 B2	9/2008	Lastovich et al.
6,743,215 B2	6/2004	Bernabei	7,427,273 B2	9/2008	Mitsui
6,764,493 B1	7/2004	Weber et al.	7,440,798 B2	10/2008	Redding, Jr.
6,780,426 B2	8/2004	Zhang et al.	7,458,944 B2	12/2008	Liste et al.
D496,101 S	9/2004	Davison	D584,151 S	1/2009	Murphy
6,800,083 B2	10/2004	Hiblar et al.	7,476,205 B2	1/2009	Erdmann
6,800,849 B2	10/2004	Staats	7,477,938 B2	1/2009	Sun et al.
D499,207 S	11/2004	Angeletta	7,482,314 B2	1/2009	Grimes et al.
D499,841 S	12/2004	Angeletta	7,485,125 B2	2/2009	Sjostrom
D502,288 S	2/2005	Longoria	7,489,989 B2	2/2009	Sukhanov et al.
D502,289 S	2/2005	Longoria	7,494,503 B2	2/2009	McDaniel
D502,569 S	3/2005	Longoria	7,507,228 B2	3/2009	Sun et al.
6,869,611 B1	3/2005	Kligman et al.	7,572,238 B2	8/2009	Rhoades
6,878,144 B2	4/2005	Altshuler et al.	7,582,067 B2	9/2009	Van Acker
6,887,260 B1	5/2005	McDaniel	7,597,900 B2	10/2009	Zimmer et al.
6,905,487 B2	6/2005	Zimmerman	7,597,901 B2	10/2009	Clarot et al.
6,911,031 B2	6/2005	Muldner	7,607,972 B2	10/2009	Groman
6,926,681 B1	8/2005	Ramey et al.	7,658,742 B2	2/2010	Karasiuk
6,938,805 B2	9/2005	Brincat	7,678,120 B2	3/2010	Shaddock
6,942,649 B2	9/2005	Ignon et al.	7,730,979 B2	6/2010	Kahrig
6,960,206 B2	11/2005	Keane	7,731,570 B2	6/2010	Groman
6,980,448 B2	12/2005	Foss et al.	7,740,651 B2	6/2010	Barak et al.
7,001,355 B2	2/2006	Nunomura et al.	7,744,582 B2	6/2010	Sadowski et al.
7,004,933 B2	2/2006	McDaniel	7,749,260 B2	7/2010	Da Silva et al.
D517,699 S	3/2006	Lansohn	7,758,537 B1	7/2010	Brunell et al.
7,031,805 B2	4/2006	Lee et al.	7,771,374 B2	8/2010	Slatkine
7,044,938 B2	5/2006	La Bianco et al.	7,780,652 B2	8/2010	MacFarland et al.
7,051,907 B2	5/2006	Brincat	7,789,886 B2	9/2010	Shaddock
7,052,503 B2	5/2006	Bernabei	D625,198 S	10/2010	Hall
D522,360 S	6/2006	Caserta et al.	7,814,915 B2	10/2010	Davenport et al.
7,062,317 B2	6/2006	Avrahami et al.	7,837,695 B2	11/2010	Hart et al.
7,069,073 B2	6/2006	Henley et al.	7,857,806 B2	12/2010	Karpowicz et al.
7,070,488 B2	7/2006	Suissa et al.	7,862,564 B2	1/2011	Goble
7,083,580 B2	8/2006	Bernabei	7,901,373 B2	3/2011	Tavger
7,087,036 B2	8/2006	Busby et al.	7,927,188 B2	4/2011	Groman
7,087,063 B2	8/2006	Carson et al.	7,951,156 B2	5/2011	Karasiuk
7,094,252 B2	8/2006	Koop	D639,164 S	6/2011	Walsh
7,108,689 B2	9/2006	Eckhouse et al.	7,981,111 B2	7/2011	Grove et al.
7,115,275 B2	10/2006	Clarot et al.	7,981,112 B1	7/2011	Neev
7,118,563 B2	10/2006	Weckwerth et al.	7,993,333 B2	8/2011	Oral et al.
7,122,029 B2	10/2006	Koop et al.	8,025,669 B1	9/2011	David et al.
7,135,011 B2	11/2006	Powers et al.	RE42,960 E	11/2011	Waldron
D533,962 S	12/2006	Angeletta	8,048,064 B2	11/2011	Hwang et al.
7,153,311 B2	12/2006	Chung	8,048,089 B2	11/2011	Ignon et al.
7,166,086 B2	1/2007	Haider et al.	8,066,716 B2	11/2011	Shaddock
D536,481 S	2/2007	Angeletta	8,088,085 B2	1/2012	Thiebaut et al.
7,172,572 B2	2/2007	Diamond et al.	8,105,295 B2	1/2012	Blott et al.
7,189,230 B2	3/2007	Knowlton	8,128,638 B2	3/2012	Karasiuk et al.
7,197,359 B1	3/2007	Tokudome et al.	8,135,475 B2	3/2012	Kreindel et al.
7,198,623 B2	4/2007	Fischer et al.	8,182,473 B2	5/2012	Altshuler et al.
7,201,765 B2	4/2007	McDaniel	D664,254 S	7/2012	Yokoyama et al.
D545,207 S	6/2007	De Baschmakoff	8,221,437 B2	7/2012	Waldron et al.
7,232,431 B1	6/2007	Weimann	8,226,663 B2	7/2012	Remsburg et al.
7,232,444 B2	6/2007	Chang	8,231,292 B2	7/2012	Rabe et al.
7,241,208 B2	7/2007	Suissa et al.	8,236,008 B2	8/2012	Boone, III et al.
7,250,045 B2	7/2007	Island et al.	8,236,036 B1	8/2012	Frost
			8,241,094 B2	8/2012	Groman
			8,273,080 B2	9/2012	Mehta
			8,276,592 B2	10/2012	Davenport et al.
			8,277,287 B2	10/2012	Hart

(56)

References Cited

U.S. PATENT DOCUMENTS

8,282,630	B2	10/2012	Neev	9,421,261	B2	8/2016	Harris et al.
8,313,480	B2	11/2012	Neev	D765,512	S	9/2016	Joulia
8,317,781	B2	11/2012	Owens et al.	9,439,964	B2	9/2016	Harris et al.
8,323,253	B2	12/2012	Hantash et al.	9,440,093	B2	9/2016	Homer
8,337,513	B2	12/2012	Shadduck	9,452,013	B2	9/2016	Manstein
8,343,116	B2	1/2013	Ignon et al.	9,468,464	B2	10/2016	Shadduck
8,360,826	B2	1/2013	Groman	9,474,886	B2	10/2016	Ignon et al.
D676,764	S	2/2013	Moore et al.	D772,481	S	11/2016	Paquet
D678,783	S	3/2013	Wilcox et al.	9,480,836	B2	11/2016	Na
8,398,621	B2	3/2013	Beerwerth et al.	9,486,615	B2	11/2016	Ignon et al.
D680,437	S	4/2013	Bartolo et al.	9,498,610	B2	11/2016	Ignon et al.
8,430,104	B2	4/2013	Hennings et al.	9,517,085	B2	12/2016	Karasiuk
8,435,234	B2	5/2013	Chan et al.	9,522,287	B2	12/2016	Owens et al.
8,475,507	B2	7/2013	Dewey et al.	9,550,052	B2 *	1/2017	Ignon A61B 50/10
8,478,396	B2	7/2013	Tsao et al.	9,566,088	B2	2/2017	Ignon et al.
8,480,721	B2	7/2013	Owens et al.	9,566,454	B2	2/2017	Barthe et al.
8,496,654	B2	7/2013	Adanny et al.	9,572,880	B2	2/2017	Harris et al.
8,496,695	B2	7/2013	Kang et al.	9,597,527	B2	3/2017	Buchholz et al.
8,535,299	B2	9/2013	Giovannoli	D782,881	S	4/2017	Seiders et al.
8,545,419	B2	10/2013	Kim	D787,054	S	5/2017	Rini et al.
8,545,489	B2	10/2013	Giovannoli	9,636,521	B2	5/2017	Isserow et al.
8,551,104	B2	10/2013	Weckwerth et al.	9,636,522	B2	5/2017	Oversluizen et al.
8,562,626	B2	10/2013	Sabir et al.	9,642,997	B2	5/2017	Ignon et al.
8,573,874	B2	11/2013	Neuner	9,662,482	B2	5/2017	Ignon et al.
8,579,916	B2	11/2013	Cheney	9,669,233	B2	6/2017	Quisenberry et al.
8,597,284	B2	12/2013	Castro	9,675,817	B2	6/2017	Isserow et al.
D697,404	S	1/2014	Johnson et al.	9,694,199	B2	7/2017	Duquet et al.
8,632,378	B2	1/2014	Groman	9,700,684	B2	7/2017	Vlodaver et al.
D699,367	S	2/2014	Lee et al.	9,731,053	B2	8/2017	Alai
8,656,931	B2	2/2014	Davenport et al.	9,744,315	B1	8/2017	Levi
8,668,552	B2	3/2014	Groman	9,775,645	B2	10/2017	Boone, III
8,679,039	B2	3/2014	Tieu et al.	9,775,646	B2	10/2017	Shadduck
8,700,176	B2	4/2014	Azar et al.	9,775,976	B2	10/2017	Greze
8,702,691	B2	4/2014	Weber et al.	9,814,485	B2	11/2017	Pratt et al.
8,702,771	B1	4/2014	Frost	9,814,647	B2	11/2017	Ajiki
8,721,662	B2	5/2014	Karasiuk	9,814,868	B2	11/2017	Ignon et al.
8,728,064	B2	5/2014	Schomacker et al.	9,814,906	B2	11/2017	McDaniel
8,740,917	B2	6/2014	Pilcher et al.	9,833,261	B2	12/2017	Boone, III et al.
D709,617	S	7/2014	Iliesco de Grimaldi et al.	9,861,442	B2	1/2018	Tankovich et al.
8,814,836	B2	8/2014	Ignon et al.	D811,225	S	2/2018	Newson
8,818,500	B2	8/2014	Duquet et al.	D811,381	S	2/2018	Morohoshi et al.
8,821,940	B2	9/2014	Harris et al.	9,918,727	B1	3/2018	Boone, III et al.
8,834,933	B2	9/2014	Harris et al.	9,949,552	B2	4/2018	Rabe et al.
8,858,570	B2	10/2014	Chang	9,950,147	B2	4/2018	Mehta
8,939,669	B2	1/2015	Le et al.	9,955,769	B2	5/2018	Rabe et al.
D722,172	S	2/2015	Amemiya et al.	9,962,220	B2	5/2018	Domankevitz
8,945,104	B2	2/2015	Boone, III et al.	9,968,800	B2	5/2018	Anderson et al.
8,945,109	B2	2/2015	Mehta	10,004,919	B2	6/2018	Lemmens et al.
8,974,442	B1	3/2015	Boss, Jr.	D822,845	S	7/2018	Shimobayashi et al.
9,017,391	B2	4/2015	McDaniel	10,010,445	B2	7/2018	Isserow et al.
9,017,392	B2	4/2015	Owens et al.	10,022,289	B2	7/2018	Ajiki et al.
9,044,582	B2	6/2015	Chang et al.	10,035,007	B2	7/2018	Ignon et al.
9,050,133	B1	6/2015	Boone, III et al.	D825,763	S	8/2018	Lim et al.
9,050,156	B2	6/2015	Groman	10,052,467	B2	8/2018	Bansal et al.
9,056,193	B2	6/2015	Ignon et al.	D829,333	S	9/2018	Shin et al.
D734,154	S	7/2015	Johnson et al.	10,076,354	B2	9/2018	Knowlton
9,072,521	B2	7/2015	Levi et al.	10,076,646	B2	9/2018	Casasanta, III et al.
9,072,533	B2	7/2015	Liu et al.	10,080,581	B2	9/2018	Knowlton
9,072,892	B2	7/2015	Owens et al.	D829,921	S	10/2018	Xiong
9,084,587	B2	7/2015	Eckhouse et al.	10,092,478	B1	10/2018	Amit
9,149,322	B2	10/2015	Knowlton	10,105,191	B2	10/2018	Blanco et al.
D743,269	S	11/2015	Pape	D833,283	S	11/2018	Rock
D743,558	S	11/2015	Kim et al.	10,130,390	B1	11/2018	Hart et al.
9,186,490	B2	11/2015	Chang et al.	10,130,827	B2	11/2018	Buchholz et al.
9,227,044	B2	1/2016	Bansal et al.	D836,781	S	12/2018	Meurer et al.
9,227,082	B2	1/2016	McDaniel	10,149,969	B2	12/2018	Greze et al.
9,233,207	B2	1/2016	Polyakov et al.	10,149,984	B2	12/2018	Modi et al.
9,271,755	B2	3/2016	Luzon et al.	10,172,644	B2	1/2019	Ignon et al.
9,278,230	B2	3/2016	Levin et al.	10,179,229	B2	1/2019	Ignon et al.
9,283,037	B2	3/2016	Bragagna et al.	10,183,183	B2	1/2019	Burdette
9,314,302	B2	4/2016	Dougal	10,188,193	B2	1/2019	Rabe et al.
9,351,792	B2	5/2016	Manstein et al.	10,206,743	B2	2/2019	Tankovich et al.
9,351,794	B2	5/2016	Suckewer et al.	10,207,034	B2	2/2019	Collins
9,375,281	B2	6/2016	Moench et al.	10,220,122	B2	3/2019	Clark, III et al.
9,421,260	B2	8/2016	Harris et al.	10,238,812	B2	3/2019	Ignon
				10,238,849	B2	3/2019	Britva et al.
				10,251,675	B2	4/2019	Ignon et al.
				10,252,044	B2	4/2019	Bock
				10,271,900	B2	4/2019	Marchitto et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

10,272,258 B2	4/2019	Quisenberry et al.	11,202,657 B2	12/2021	Ignon et al.
D851,759 S	6/2019	Jones et al.	11,213,321 B2	1/2022	Ignon et al.
10,307,330 B1	6/2019	Sedic	11,224,728 B2	1/2022	Ignon et al.
10,308,378 B2	6/2019	Goodwin et al.	11,241,357 B2	2/2022	Ignon et al.
10,314,378 B2	6/2019	Rabe et al.	11,247,039 B2	2/2022	Schwarz
10,321,948 B2	6/2019	Knowlton	11,278,101 B2	3/2022	Jeannin et al.
10,322,233 B2	6/2019	Hanson et al.	11,291,474 B2	4/2022	Nicolas et al.
10,328,277 B2	6/2019	Modi et al.	11,291,498 B2	4/2022	Slatkine et al.
D852,962 S	7/2019	Chang	11,311,721 B2	4/2022	Ebbers et al.
10,335,191 B2	7/2019	Knowlton	11,337,745 B2	5/2022	Kim
10,357,641 B2	7/2019	Ignon et al.	11,337,755 B2	5/2022	Hancock et al.
10,357,642 B2	7/2019	Ignon et al.	11,351,063 B2	6/2022	Locke et al.
10,334,933 B2	8/2019	Rosario et al.	11,419,678 B2	8/2022	Deem et al.
10,369,073 B2	8/2019	Rosario et al.	D964,581 S	9/2022	Guo
10,413,359 B2	9/2019	Felsenstein et al.	11,446,477 B2	9/2022	Ignon et al.
D861,913 S	10/2019	Stamm et al.	11,452,852 B2	9/2022	Quan et al.
10,456,197 B2	10/2019	Felsenstein et al.	11,452,883 B1	9/2022	Marchese et al.
10,456,321 B2	10/2019	Shaddock	11,497,553 B2	11/2022	Reinhard et al.
10,456,567 B2	10/2019	Streeter	11,504,148 B2	11/2022	Friend
D867,587 S	11/2019	Holtz	11,517,350 B2	12/2022	Ignon et al.
10,463,429 B2	11/2019	Deem et al.	11,540,882 B2	1/2023	Masotti et al.
10,471,274 B2	11/2019	Liu et al.	11,547,840 B2	1/2023	Ignon et al.
10,485,983 B1	11/2019	Boone, III et al.	D979,782 S	2/2023	Sung et al.
D868,981 S	12/2019	Salamon et al.	11,590,345 B2	2/2023	Danitz et al.
D873,430 S	1/2020	Accolla	11,602,629 B2	3/2023	Schwarz et al.
D873,481 S	1/2020	Larkin	11,612,726 B2	3/2023	Ignon et al.
10,524,835 B2	1/2020	Shaddock et al.	D994,134 S	8/2023	Lim
10,537,304 B2	1/2020	Barthe et al.	11,717,326 B2	8/2023	Ignon et al.
10,537,640 B2	1/2020	Harris et al.	D998,143 S	9/2023	Nagao et al.
10,556,096 B2	2/2020	Ignon et al.	11,744,999 B2	9/2023	Ignon et al.
10,556,097 B2	2/2020	Ignon et al.	11,806,495 B2	11/2023	Ignon et al.
10,583,037 B2	3/2020	Isserow et al.	D1,011,541 S	1/2024	Yu
D886,370 S	6/2020	Soutelo Gomes	11,865,287 B2	1/2024	Ignon et al.
D886,372 S	6/2020	Weinrich	11,883,621 B2	1/2024	Ignon et al.
D887,571 S	6/2020	Liu	11,903,615 B2	2/2024	Ignon et al.
10,667,985 B2	6/2020	Decaux et al.	D1,016,615 S	3/2024	Rozporka et al.
10,675,481 B1	6/2020	Tankovich	11,925,780 B2	3/2024	Ignon et al.
10,688,290 B1	6/2020	Yuval	2001/0023351 A1	9/2001	Eilers
10,702,328 B2	7/2020	Slatkine et al.	2001/0037118 A1	11/2001	Shaddock
10,716,924 B2	7/2020	Knowlton	2001/0049511 A1 *	12/2001	Coleman A61H 9/00 604/290
D893,024 S	8/2020	Whiteside	2002/0016601 A1	2/2002	Shaddock
10,736,653 B2	8/2020	Knowlton	2002/0040199 A1	4/2002	Klopotek
10,737,080 B2	8/2020	Patterson	2002/0041891 A1	4/2002	Cheski
10,758,261 B2	9/2020	Richardson	2002/0058952 A1	5/2002	Weber et al.
10,772,658 B2	9/2020	Knowlton	2002/0099356 A1	7/2002	Unger et al.
10,792,382 B2	10/2020	Rafko	2002/0107527 A1	8/2002	Burres
10,799,285 B2	10/2020	Mulholland	2002/0128663 A1	9/2002	Mercier et al.
10,799,430 B2	10/2020	Danto	2002/0133110 A1	9/2002	Citow
10,813,694 B2	10/2020	Johnson et al.	2002/0133176 A1	9/2002	Parkin et al.
10,835,287 B2	11/2020	Shaddock et al.	2002/0151826 A1	10/2002	Ramey et al.
10,835,726 B2	11/2020	Redding, Jr.	2002/0151908 A1	10/2002	Mallett, Sr. et al.
D903,889 S	12/2020	Luo et al.	2002/0162863 A1	11/2002	Brincat
10,850,095 B2	12/2020	Ebbers et al.	2002/0188261 A1	12/2002	Hruska
10,856,900 B2	12/2020	Knowlton	2002/0198488 A1	12/2002	Yao
10,860,026 B2	12/2020	Nguyen et al.	2003/0012415 A1	1/2003	Cossel
10,874,579 B1	12/2020	Rembert	2003/0018252 A1 *	1/2003	Duchon A61M 5/172 600/432
D908,282 S	1/2021	Kim	2003/0060834 A1	3/2003	Muldner
10,893,907 B2	1/2021	Kim	2003/0093040 A1	5/2003	Mikszta et al.
10,912,428 B2	2/2021	Daffer	2003/0093089 A1	5/2003	Greenberg
10,918,190 B2	2/2021	Laudati	2003/0097139 A1	5/2003	Karasiuk
10,946,191 B2	3/2021	Cazares Delgadillo	2003/0135388 A1	7/2003	Martucci et al.
10,952,811 B2	3/2021	Blanco et al.	2003/0167032 A1	9/2003	Ignon et al.
10,952,907 B1	3/2021	Carver	2003/0187462 A1	10/2003	Chang
D917,290 S	4/2021	Bravman et al.	2003/0208159 A1	11/2003	Ignon et al.
10,980,592 B2	4/2021	Horton et al.	2003/0212127 A1	11/2003	Glassman et al.
10,993,743 B2	5/2021	Ignon et al.	2003/0212415 A1	11/2003	Karasiuk
11,020,577 B2	6/2021	Ignon et al.	2004/0005349 A1	1/2004	Neev
11,045,661 B2	6/2021	Oversluizen et al.	2004/0010222 A1	1/2004	Nunomura et al.
D927,008 S	8/2021	Rappaport	2004/0010269 A1	1/2004	Grimes et al.
D928,977 S	8/2021	Dijkstra	2004/0015139 A1	1/2004	La Bianco
11,083,515 B2	8/2021	Slatkine et al.	2004/0051368 A1	3/2004	Caputo et al.
11,123,039 B2	9/2021	Barthe et al.	2004/0087972 A1	5/2004	Mulholland et al.
11,141,761 B2	10/2021	Connelly et al.	2004/0092895 A1	5/2004	Harmon
11,154,723 B2	10/2021	Lee	2004/0092959 A1	5/2004	Bernaz
11,172,978 B2	11/2021	Wootten et al.	2004/0097967 A1	5/2004	Ignon
			2004/0122447 A1	6/2004	Harmon et al.
			2004/0127914 A1	7/2004	Chung

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0138680	A1	7/2004	Twitchell et al.	2007/0270738	A1	11/2007	Wu et al.
2004/0162565	A1	8/2004	Carson et al.	2008/0009802	A1	1/2008	Lambino et al.
2004/0166172	A1	8/2004	Rosati et al.	2008/0015555	A1	1/2008	Manstein et al.
2004/0176823	A1	9/2004	Island et al.	2008/0027328	A1	1/2008	Klopotek et al.
2004/0210167	A1	10/2004	Webster	2008/0027518	A1	1/2008	Island et al.
2004/0210280	A1	10/2004	Liedtke	2008/0091126	A1	4/2008	Greenburg
2004/0219179	A1	11/2004	McDaniel	2008/0091179	A1	4/2008	Durkin et al.
2004/0229295	A1	11/2004	Marchitto et al.	2008/0103563	A1	5/2008	Powell
2004/0236291	A1	11/2004	Zelickson et al.	2008/0119781	A1	5/2008	King
2004/0236375	A1	11/2004	Redding, Jr.	2008/0132914	A1	6/2008	Bossard et al.
2004/0243149	A1	12/2004	Lee, Jr.	2008/0139974	A1	6/2008	Da Silva
2004/0254587	A1	12/2004	Park	2008/0146970	A1	6/2008	Litman et al.
2004/0267285	A1	12/2004	Chang	2008/0154161	A1	6/2008	Abbott
2005/0015077	A1	1/2005	Kuklin et al.	2008/0154183	A1	6/2008	Baker et al.
2005/0037034	A1	2/2005	Rhoades	2008/0161799	A1	7/2008	Stangenes et al.
2005/0038377	A1	2/2005	Redding, Jr.	2008/0188840	A1	8/2008	Johnson et al.
2005/0038448	A1	2/2005	Chung	2008/0193493	A1	8/2008	Rhoades
2005/0059940	A1	3/2005	Weber et al.	2008/0200861	A1	8/2008	Shalev et al.
2005/0065461	A1	3/2005	Redding, Jr.	2008/0200863	A1	8/2008	Chomas et al.
2005/0070977	A1	3/2005	Molina	2008/0208146	A1	8/2008	Brandwein et al.
2005/0075599	A1	4/2005	Redding, Jr.	2008/0208179	A1	8/2008	Chan et al.
2005/0080465	A1	4/2005	Zelickson et al.	2008/0214987	A1	9/2008	Xu
2005/0084509	A1	4/2005	Bernstein	2008/0215068	A1	9/2008	Hart et al.
2005/0148958	A1	7/2005	Rucinski	2008/0221548	A1	9/2008	Danenberg et al.
2005/0154333	A1	7/2005	Mulholland et al.	2008/0234626	A1	9/2008	Chelak
2005/0203111	A1	9/2005	David	2008/0243039	A1	10/2008	Rhoades
2005/0203593	A1	9/2005	Shanks et al.	2008/0287864	A1	11/2008	Rosenberg
2005/0209611	A1	9/2005	Greenberg	2008/0300529	A1	12/2008	Reinstein
2005/0245180	A1	11/2005	Suissa et al.	2008/0300552	A1	12/2008	Cichocki et al.
2005/0283176	A1	12/2005	Law	2009/0048557	A1	2/2009	Yeshurun et al.
2006/0002960	A1	1/2006	Zoetewij et al.	2009/0053390	A1	2/2009	Sakou et al.
2006/0015059	A1	1/2006	Redding, Jr.	2009/0062815	A1	3/2009	Karasiuk et al.
2006/0058714	A1	3/2006	Rhoades	2009/0099091	A1	4/2009	Hantash
2006/0100567	A1	5/2006	Marchitto et al.	2009/0099093	A1	4/2009	Hantash
2006/0116674	A1	6/2006	Goble et al.	2009/0118684	A1	5/2009	Da Silva et al.
2006/0161178	A1	7/2006	Lee	2009/0124985	A1	5/2009	Hasenoechrl et al.
2006/0184071	A1	8/2006	Klopotek	2009/0132012	A1	5/2009	Shanks
2006/0189964	A1	8/2006	Anderson	2009/0138026	A1	5/2009	Wu
2006/0191562	A1	8/2006	Numomura	2009/0171191	A1	7/2009	Patrick et al.
2006/0200099	A1	9/2006	La Bianco et al.	2009/0171194	A1	7/2009	Patrick et al.
2006/0200213	A1	9/2006	McDaniel	2009/0177171	A1	7/2009	Ignon et al.
2006/0212025	A1	9/2006	McDaniel	2009/0192442	A1	7/2009	Ignon et al.
2006/0212029	A1	9/2006	Villacampa et al.	2009/0222023	A1	9/2009	Boone, III et al.
2006/0222445	A1	10/2006	Chuang	2009/0254014	A1	10/2009	Son
2006/0235371	A1	10/2006	Wakamatsu et al.	2009/0299237	A1	12/2009	Rhoades
2006/0253078	A1	11/2006	Wu et al.	2010/0023003	A1	1/2010	Mulholland
2006/0253079	A1	11/2006	McDonough et al.	2010/0036298	A1	2/2010	Fuster
2006/0253125	A1	11/2006	Ignon	2010/0045427	A1	2/2010	Boone, III et al.
2006/0264893	A1	11/2006	Sage, Jr. et al.	2010/0048980	A1	2/2010	De Jong et al.
2006/0264926	A1	11/2006	Kochamba	2010/0049177	A1	2/2010	Boone, III et al.
2006/0269580	A1	11/2006	Cole et al.	2010/0049210	A1	2/2010	Boone, III et al.
2006/0278661	A1	12/2006	Cooper et al.	2010/0056847	A1	3/2010	De Jong et al.
2007/0005078	A1	1/2007	Hart et al.	2010/0063565	A1	3/2010	Beerwerth et al.
2007/0020321	A1	1/2007	Redding et al.	2010/0217357	A1	8/2010	Da Silva
2007/0027411	A1	2/2007	Ella et al.	2010/0305495	A1	12/2010	Anderson et al.
2007/0043382	A1	2/2007	Cheney	2011/0054490	A1	3/2011	Hart
2007/0049901	A1	3/2007	Wu et al.	2011/0060270	A1	3/2011	Eppstein
2007/0065515	A1	3/2007	Key	2011/0066162	A1	3/2011	Cohen
2007/0073327	A1	3/2007	Giovannoli	2011/0082415	A1	4/2011	Ignon et al.
2007/0078290	A1	4/2007	Esenaliev	2011/0067761	A1	6/2011	King
2007/0088245	A1	4/2007	Babaev et al.	2011/0144410	A1	6/2011	Kennedy
2007/0088371	A1	4/2007	Karasiuk	2011/0190726	A1	8/2011	Hantash et al.
2007/0093694	A1	4/2007	Fassuliotis et al.	2011/0251523	A1	10/2011	Kim
2007/0123808	A1	5/2007	Rhoades	2011/0264028	A1	10/2011	Ramdas et al.
2007/0139630	A1	6/2007	Kleman et al.	2011/0270137	A1	11/2011	Goren et al.
2007/0149991	A1	6/2007	Mulholland	2011/0270364	A1	11/2011	Kreindel
2007/0154502	A1	7/2007	Hattendorf et al.	2011/0295273	A1	12/2011	Waldron et al.
2007/0156124	A1	7/2007	Ignon et al.	2012/0022435	A1	1/2012	Ignon et al.
2007/0178121	A1	8/2007	First et al.	2012/0041338	A1	2/2012	Chickering, III et al.
2007/0198031	A1	8/2007	Kellogg	2012/0041523	A1	2/2012	Solomon et al.
2007/0232987	A1	10/2007	Diaz et al.	2012/0109041	A1	5/2012	Munz
2007/0239079	A1	10/2007	Manstein et al.	2012/0109043	A1	5/2012	Zhou et al.
2007/0239173	A1	10/2007	Khalaj	2012/0136374	A1	5/2012	Karasiuk
2007/0255355	A1	11/2007	Altshuler et al.	2012/0171636	A1	7/2012	Groman
2007/0264625	A1	11/2007	DeBenedictis et al.	2012/0259252	A1	10/2012	Thorn-Leeson et al.
				2012/0289885	A1	11/2012	Cottrell
				2012/0302929	A1	11/2012	Tkachenko
				2013/0004230	A1	1/2013	Kirk, III et al.
				2013/0018317	A1	1/2013	Bobroff et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2013/0066336	A1	3/2013	Boone, III et al.	2019/0224501	A1	7/2019	Burdette
2013/0085421	A1	4/2013	Gillespie et al.	2019/0239939	A1	8/2019	Boll et al.
2013/0096546	A1	4/2013	Mirkov et al.	2019/0240110	A1	8/2019	Sedic
2013/0096577	A1	4/2013	Shadduck	2019/0240502	A1	8/2019	Anderson et al.
2013/0144207	A1	6/2013	Gonon	2019/0257320	A1	8/2019	Petit et al.
2013/0144280	A1	6/2013	Eckhouse et al.	2019/0274759	A1	9/2019	Royon et al.
2013/0158547	A1	6/2013	David	2019/0275320	A1	9/2019	Kim et al.
2013/0204238	A1	8/2013	Lederman et al.	2019/0366067	A1	12/2019	Ginggen et al.
2013/0226075	A1	8/2013	Hennings et al.	2020/0009007	A1	1/2020	Shadduck
2013/0226269	A1	8/2013	Eckhouse et al.	2020/0016342	A1	1/2020	Ignon
2013/0261534	A1	10/2013	Niezgodna et al.	2020/0030627	A1	1/2020	Eltorai et al.
2013/0268032	A1	10/2013	Neev	2020/0093945	A1	3/2020	Jeong
2013/0296807	A1	11/2013	Lintern et al.	2020/0101312	A1	4/2020	Pai et al.
2013/0310906	A1	11/2013	Neev	2020/0114116	A1	4/2020	Dubey et al.
2013/0317314	A1	11/2013	Lampson	2020/0121354	A1	4/2020	Ginggen et al.
2013/0345616	A1	12/2013	Chang	2020/0171288	A1	6/2020	Ignon et al.
2014/0031801	A1	1/2014	Giovannoli	2020/0171289	A1	6/2020	Ignon et al.
2014/0079686	A1	3/2014	Barman et al.	2020/0179220	A1	6/2020	Jablow
2014/0081251	A1	3/2014	Giovannoli	2020/0206072	A1	7/2020	Capelli et al.
2014/0094718	A1	4/2014	Feldman	2020/0254273	A1	8/2020	Jafari et al.
2014/0114234	A1	4/2014	Redding, Jr.	2020/0275945	A1	9/2020	Knowlton
2014/0135798	A1	5/2014	David	2020/0288843	A1	9/2020	Verheem
2014/0234004	A1	8/2014	Thorpe et al.	2020/0289161	A1	9/2020	Scooros
2014/0243589	A1	8/2014	Rowan	2020/0306555	A1	10/2020	Ebbesson
2014/0316492	A1	10/2014	Min et al.	2020/0316270	A1	10/2020	Dijkstra et al.
2014/0343481	A1	11/2014	Ignon	2020/0330754	A1	10/2020	Kim et al.
2014/0378887	A1	12/2014	Chang et al.	2020/0338586	A1	10/2020	Park
2015/0039060	A1	2/2015	Paulussen et al.	2020/0367961	A1	11/2020	Podmore et al.
2015/0141877	A1	5/2015	Feldman	2020/0390468	A1	12/2020	Alexander
2015/0157496	A1	6/2015	Horton et al.	2021/0001148	A1	1/2021	Verheem
2015/0202007	A1	7/2015	Mainstein et al.	2021/0052292	A1	2/2021	Karni
2015/0231379	A1	8/2015	Ignon et al.	2021/0085367	A1	3/2021	Shadduck et al.
2015/0272623	A1	10/2015	Ignon et al.	2021/0128416	A1	5/2021	Danto
2015/0313993	A1	11/2015	Bock	2021/0145479	A1	5/2021	Ignon et al.
2015/0351868	A1	12/2015	Groman	2021/0154093	A1	5/2021	Boone, III et al.
2016/0015962	A1	1/2016	Maragheh et al.	2021/0154455	A1	5/2021	Ignon et al.
2016/0018100	A1	1/2016	Batt et al.	2021/0170150	A1	6/2021	Hong et al.
2016/0089525	A1	3/2016	Greze et al.	2021/0220631	A1	7/2021	Ok et al.
2016/0175609	A1	6/2016	Dye et al.	2021/0236342	A1	8/2021	Long et al.
2016/0220849	A1	8/2016	Knowlton	2021/0236347	A1	8/2021	Carver
2016/0235257	A1	8/2016	Daffer	2021/0236836	A1	8/2021	Schwarz et al.
2016/0250415	A1	9/2016	Yagi et al.	2021/0242657	A1	8/2021	Yi et al.
2016/0256671	A1	9/2016	Ignon et al.	2021/0259914	A1	8/2021	Holbert
2016/0270850	A1	9/2016	Manstein et al.	2021/0267625	A1	9/2021	Carver
2016/0270851	A1	9/2016	Moench et al.	2021/0268304	A1	9/2021	Lee
2016/0287333	A1	10/2016	Morrison	2021/0275406	A1	9/2021	Danto
2016/0324578	A1	11/2016	Manstein et al.	2021/0282855	A1	9/2021	Boinagrov et al.
2017/0043150	A1	2/2017	Kim	2021/0283421	A1	9/2021	Kang et al.
2017/0065829	A1	3/2017	Ku	2021/0290430	A1	9/2021	Kim
2017/0106206	A1	4/2017	Seckel	2021/0330356	A1	10/2021	Del Rosario et al.
2017/0128319	A1	5/2017	Decaux et al.	2021/0353922	A1	11/2021	Ignon et al.
2017/0157419	A1	6/2017	Jeong	2021/0361525	A1	11/2021	Park et al.
2017/0196759	A1	7/2017	Palomaki et al.	2021/0370049	A1	12/2021	Moss et al.
2017/0209894	A1	7/2017	Sporrer	2021/0370089	A1	12/2021	Anash
2017/0252105	A1	9/2017	Deem et al.	2021/0393478	A1	12/2021	Bhatti
2017/0291007	A1	10/2017	Dubey et al.	2021/0393974	A1	12/2021	Kim et al.
2017/0340356	A1	11/2017	Presser et al.	2021/0393975	A1	12/2021	Eltorai et al.
2017/0343308	A1	11/2017	Wojciechowski, III et al.	2021/0395071	A1	12/2021	Zubrum et al.
2018/0008500	A1	1/2018	Anderson et al.	2021/0402208	A1	12/2021	Edgar
2018/0140329	A1	5/2018	Beijens et al.	2022/0001198	A1	1/2022	Lee
2018/0185675	A1	7/2018	Kern et al.	2022/0001199	A1	1/2022	Beerwerth et al.
2018/0310979	A1	11/2018	Peled et al.	2022/0008122	A1	1/2022	Johnston et al.
2018/0318568	A1	11/2018	Ignon et al.	2022/0032082	A1	2/2022	Shenfarber et al.
2018/0326191	A1	11/2018	Bansal et al.	2022/0054189	A1	2/2022	Wootten
2019/0009110	A1	1/2019	Gross et al.	2022/0071491	A1	3/2022	Bae et al.
2019/0009111	A1	1/2019	Myhr et al.	2022/0072332	A1	3/2022	Park et al.
2019/0070069	A1	3/2019	Gertner et al.	2022/0087891	A1	3/2022	Goodman et al.
2019/0076193	A1	3/2019	Clementi et al.	2022/0111198	A1	4/2022	Jung
2019/0083161	A1	3/2019	Harle et al.	2022/0117632	A1	4/2022	Walker et al.
2019/0133642	A1	5/2019	Ignon et al.	2022/0125706	A1	4/2022	Horinek et al.
2019/0143089	A1	5/2019	Ignon et al.	2022/0126014	A1	4/2022	Cederna et al.
2019/0151637	A1	5/2019	Groop et al.	2022/0133407	A1	5/2022	Anderson et al.
2019/0168016	A1	6/2019	Anderson et al.	2022/0175443	A1	6/2022	Slatkine et al.
2019/0183562	A1	6/2019	Widgerow	2022/0176092	A1	6/2022	Quan et al.
2019/0209859	A1	7/2019	Quisenberry et al.	2022/0203112	A1	6/2022	Iger et al.
				2022/0211424	A1	7/2022	Wootten et al.
				2022/0211988	A1	7/2022	Ignon et al.
				2022/0218562	A1	7/2022	Capelli et al.
				2022/0226668	A1	7/2022	Lee et al.

(56)

References Cited**U.S. PATENT DOCUMENTS**

2022/0233400	A1	7/2022	Oh et al.
2022/0241107	A1	8/2022	Kim et al.
2022/0241146	A1	8/2022	Jeong
2022/0268536	A1	8/2022	Stephenson et al.
2022/0287910	A9	9/2022	Boone et al.
2022/0312940	A1	10/2022	Hong et al.
2022/0362529	A1	11/2022	Castro
2022/0401714	A1	12/2022	Quan et al.
2022/0409276	A1	12/2022	Choi
2023/0000523	A1	1/2023	Nicolas et al.
2023/0012684	A1	1/2023	Ignon et al.
2023/0014299	A1	1/2023	Lee, Jr. et al.
2023/0018295	A1	1/2023	Ignon et al.
2023/0019979	A1	1/2023	Deem et al.
2023/0033217	A1	2/2023	Ignon et al.
2023/0033761	A1	2/2023	Ignon et al.
2023/0042047	A1	2/2023	Kim et al.
2023/0055346	A1	2/2023	Fortkort et al.
2023/0062185	A1	3/2023	Nazarian et al.
2023/0104221	A1	4/2023	Aharon
2023/0123145	A1	4/2023	Ko
2023/0158282	A1	5/2023	Ignon et al.
2024/0017046	A1	1/2024	Nebriagic et al.
2024/0075263	A1	3/2024	Ignon et al.
2024/0139482	A1	5/2024	Ignon et al.

FOREIGN PATENT DOCUMENTS

CA	2340154	9/2002
CA	2784209	8/2011
CN	3292006	4/2003
CN	1708261	12/2005
CN	107920948	4/2018
CN	305941358	7/2020
CN	306109314	10/2020
CN	306995346	12/2021
CN	308188687	8/2023
DE	599521	7/1934
DE	2415633	10/1975
DE	3338057	8/1984
DE	3421390	12/1985
DE	234608	4/1986
DE	3503343	8/1986
DE	8330191	6/1987
DE	3740902	12/1988
DE	4237940	5/1993
DE	29808395	8/1998
DE	10-2004-015815	11/2005
EM	8794184-0001	12/2021
EM	8880371-0001	5/2022
EM	015024621-0002	6/2023
EP	0258901	9/1987
EP	0479121	4/1992
EP	0564392	3/1993
EP	0784997	7/1997
EP	1238643	4/2000
EP	1453558	9/2004
EP	2206483	7/2010
EP	2544563	9/2015
EP	2106780	3/2016
EP	2865867	5/2016
EP	3217899	5/2016
EP	2240099	2/2018
EP	2967633	4/2018
EP	3302319	4/2018
EP	3319573	5/2018
EP	3340908	7/2018
EP	2451367	1/2020
EP	3388006	3/2020
EP	2618797	4/2020
EP	3237055	8/2020
EP	3795204	3/2021
EP	3437575	4/2021
ES	1037776	4/1998
FR	2712172	5/1995

FR	2773461	7/1999
GB	1372609	10/1974
GB	2306351	5/1997
GB	2585500	1/2021
GB	6228949	3/2022
GB	6228947	9/2022
IT	553076	12/1956
IT	1184922	3/1985
JP	S55-034863	8/1963
JP	S54-63580 A	5/1979
JP	H05-042060	2/1993
JP	1993-088552	12/1993
JP	1997-294747	11/1997
JP	2003-534881	11/2003
JP	2003-339713	12/2003
JP	2004-275721	10/2004
JP	2006-503627	2/2006
JP	2006-204767	10/2006
JP	2012-527967	11/2012
JP	2013-215621	10/2013
JP	D1581877	7/2017
JP	D1609357	6/2018
JP	2018-527052	9/2018
JP	D1675782	1/2021
KR	20-0280320	7/2002
KR	10-20070070173	7/2007
KR	10-2018-0030607	3/2018
KR	10-1836310	3/2018
KR	301238287.0000	11/2023
KR	301238288.0000	11/2023
TW	D155201	8/2013
TW	D176752	6/2016
TW	D214226	9/2021
WO	WO 1994/024980	11/1994
WO	WO 1997/000707	1/1997
WO	WO 1997/011650	3/1997
WO	WO 1999/23951	5/1999
WO	WO 1999/37229	7/1999
WO	WO 2000/015300	3/2000
WO	WO 2000/79540	12/2000
WO	WO 2001/93931	12/2001
WO	WO 2004/108091	12/2001
WO	WO 2003/073917	9/2003
WO	WO 2004/037098	5/2004
WO	WO 2004/037287	5/2004
WO	WO 2005/061042	7/2005
WO	WO 2005/070313	8/2005
WO	WO 2006/018731	2/2006
WO	WO 2006/031413	3/2006
WO	WO 2007/114904	10/2007
WO	WO 2008/012324	1/2008
WO	WO 2009/086182	7/2009
WO	WO 2009/088884	7/2009
WO	WO 2009/097451	8/2009
WO	WO 2010/022396	2/2010
WO	WO 2010/068960	6/2010
WO	WO 2010/151704	12/2010
WO	WO 2011/006009	1/2011
WO	WO 2011/110840	9/2011
WO	WO 2012/131623	10/2012
WO	WO 2012/145667	10/2012
WO	WO 2013/030117	3/2013
WO	WO 2014/091035	6/2014
WO	WO 2014/151104	9/2014
WO	WO 2016/052818	4/2016
WO	WO 2016/106396	6/2016
WO	WO 2017/007939	1/2017
WO	WO 2017/111481	6/2017
WO	WO 2021/018765	2/2021
WO	WO 2021/113343	6/2021
WO	WO 2022/099318	5/2022
WO	WO 2023/039524	3/2023

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 2023/064718	4/2023
WO	WO 2023/164572	8/2023

OTHER PUBLICATIONS

Amazon.com: Osaki LED Therapy Dome, posted date unavailable (retrieved online Mar. 29, 2024), from <https://www.amazon.com/Osaki-LED-Therapy-Dome/dp/B08NN3BS7L> (2024).

"BeautyBio: GLOfacial Hydro-Infusion deep pore cleansing + Blue LED clarifying tool", found online at amazon.com Sep. 26, 2023, ref. dated Nov. 15, 2022, retrieved <https://www.amazon.com/GLOfacial-Hydro-Infusion-Deep-Cleansing-Clarifying/dp/B0BGJLMSZP/>.

Celluma LITE Compact LED Light Therapy Device for Travel, posted date unavailable, (retrieved online Mar. 29, 2024), from <https://www.celluma.com/products/celluma-lite> (2024).

Elipsa-LightSlim, posted date unavailable, (retrieved online Mar. 29, 2024), from <https://www.lightslim.com/products/lightslim-elipsa> (2024).

"Healthline: What is a HydraFacial and how does it work", found online at healthline.com Sep. 26, 2023, Ref. dated Dec. 9, 2020, <https://www.healthline.com/health/what-is-hydrfacial>.

HydraFacial MD Karma Spa Lounge & Beauty Bar, posted date unavailable (retrieved online Mar. 29, 2024), from <https://www.karmabeautybar.com/hydrfacial-md> (2024).

"InStyle: Why the HydraFacial is one of the most popular in-office treatments", found online at instyle.com on Sep. 26, 2023, ref. dated Jun. 12, 2023, <https://www.instyle.com/beauty/skin/hydrfacial-treatment-facts>.

"Microderm Glo: Glo Mini", found online at microdermglo.com Sep. 26, 2023, ref. dated Sep. 27, 2019, <https://www.microdermglo.com/collections/microdermabrasion-machines>.

Amazon, Fazjeune 7 Color LED Light, LED Face Mask Skin Rejuvenation PDT Photon Facial Skin Care Mask Skin Tightening Lamp SPA Face Device Beauty Salon Equipment Anti-aging Remove Wrinkle, Customer reviewed on Sep. 2020, retrieved from internet at https://www.amazon.com/FAZJEUNE-Rejuvenation-Tightening-Equipment-Anti-aging/dp/B08B4M8RQQ/ref=psdc_11061121_t3_B08ZSPZSF4.

Beautimate adjustable Hydra Needle Microneedling Serum Applicator, <https://www.beautimate.com/products/adjustable-hydra-needle>, first accessed Aug. 12, 2023.

File History of Reissue U.S. Appl. No. 11/027,590, filed Dec. 29, 2004 (Reissue of U.S. Pat. No. 6,500,183, issued Dec. 31, 2002).

File History of Reexamination No. 90/007,683 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001).

File History of Reexamination No. 90/013,284, filed Jul. 2, 2014 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001).

Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26.

Ditre et al., Effect of a-hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructural study, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195.

Harris et al., Combining Manual Dermabrasion with Low Strength Trichloroacetic Acid to Improve Antinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442.

HydraFacial® Tower—User guide. Edge Systems. Revised Jun. 23, 2016. p. No. 16.

HydraFacial Hydropeel Vortex Fusion Tips, <https://mergesouq.com/products/hydrfacial-hydropeel-vortex-fusion-tips>, first accessed Aug. 12, 2023.

Microdermabrader Pepita Instruction Manual, Mattioli Engineering S.R.L., PEP_USA2.doc Rev 1.1, Sep. 29, 1997.

* cited by examiner






FIG. 1

FIG. 2A









FIG. 3






FIG. 5B




FIG. 5D




FIG. 5A




FIG. 5C




FIG. 6B




FIG. 6D




FIG. 6A




FIG. 6C






FIG. 7B




FIG. 7D




FIG. 7A




FIG. 7C




FIG. 8B




FIG. 8D




FIG. 8A









FIG. 8C








FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D





FIG. 11E






FIG. 13A




FIG. 13B




FIG. 14A





FIG. 14B






FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E




FIG. 16




FIG. 17




FIG. 18




FIG. 19

DEVICES AND METHODS FOR TREATING SKIN

REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 18/094,884 filed Jan. 9, 2023 and issued as U.S. Pat. No. 11,865,287 on Jan. 9, 2024, which is a continuation of U.S. patent application Ser. No. 17/165,820 filed Feb. 2, 2021 and issued as U.S. Pat. No. 11,547,840 on Jan. 10, 2023, which is a continuation of U.S. patent application Ser. No. 16/517,268 filed Jul. 19, 2019 and issued as U.S. Pat. No. 11,446,477 on Sep. 20, 2022, which is a continuation of U.S. patent application Ser. No. 15/660,750 filed Jul. 26, 2017 and issued as U.S. Pat. No. 10,357,641 on Jul. 23, 2019, which is a continuation of U.S. patent application Ser. No. 14/700,789 filed Apr. 30, 2015 and issued as U.S. Pat. No. 9,814,868 on Nov. 14, 2017, which is a continuation of U.S. patent application Ser. No. 13/267,554 filed Oct. 6, 2011 and issued as U.S. Pat. No. 9,474,886 on Oct. 25, 2016, which is a continuation of U.S. patent application Ser. No. 11/392,348 filed Mar. 29, 2006 and issued as U.S. Pat. No. 8,048,089 on Nov. 1, 2011, which claims the benefit of U.S. Provisional Application No. 60/755,310 filed Dec. 30, 2005 and U.S. Provisional Application No. 60/764,668 filed Feb. 2, 2006. The entireties of all of the aforementioned applications are hereby incorporated by reference herein.

BACKGROUND

Field

The invention relates in general to the field of skin treatment, and more specifically to apparatuses and methods for treating a person's skin.

Description of the Related Art

Abrasion of the outer layer or epidermis of the skin is desirable to smooth or blend scars, blemishes, or other skin conditions that may be caused by, for example, acne, sun exposure, and aging. Standard techniques used to abrade the skin have generally been separated into two fields referred to as dermabrasion and microdermabrasion. Both techniques remove portions of the epidermis called the stratum corneum, which the body interprets as a mild injury. The body then replaces the lost skin cells, resulting in a new outer layer of skin. Additionally, despite the mild edema and erythema associated with the procedures, the skin looks and feels smoother because of the new outer layer of skin.

Dermabrasion refers to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece with an abrasive element that is often in the form of a burr, wheel, or disc. This process tends to be painful and messy. In fact, the procedure is sometimes painful enough to require a local anesthetic. Dermabrasion leaves the skin red and raw-looking. The removed skin can take several months to regrow and heal. Recent efforts have led to the use of lasers instead of abrasive elements, which have resulted in less bleeding, but the pain and mess remains.

Efforts have been made to decrease the mess caused by the process waste, such as removed skin and blood, by adding a suction element. As the process waste is drawn into the suction opening, skin that has not been removed is also pulled against the grit surrounding the suction opening, so the procedure remains fairly messy due to the abrasion that takes place outside of the handpiece by the grit.

Microdermabrasion refers generally to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece emitting a stream of sand or grit. For example, a handpiece can be used to direct an air flow containing tiny crystals of aluminum oxide, sodium chloride, or sodium bicarbonate. The momentum of the grit tends to wear away two to three cell layers of the skin with each pass of the handpiece. Alternatively, new "crystal-free" microdermabrasion techniques utilize a diamond-tipped handpiece without a stream of grit.

Efforts to add a suction element have been more successful in microdermabrasion than in dermabrasion because the handpiece applying the stream of grit is more controllable to a localized area. That is, as the removed skin is drawn into the suction opening, skin that has not been removed is also pulled towards the handpiece where it is treated with the grit stream, allowing for simultaneous local treatment and suction.

Microdermabrasion removes moisture from the skin, so the procedure is always followed by the application of moisturizing creams. However, similar to topical application of moisturizing creams prior to microdermabrasion, the moisturizing elements only work as deep as the active ingredients can passively migrate through the remaining epidermis.

SUMMARY

In some embodiments, an apparatus for treating skin has a console with a user input device and a handpiece assembly. The handpiece assembly is configured to treat skin. A fluid line provides fluid communication between the console and the handpiece assembly. A manifold system is coupled to the console and controlled by the user input device, such as a computer, touchscreen, keyboard, and the like. The manifold system is configured to hold releasably a plurality of fluid sources and deliver fluid from at least one of the plurality of fluid sources to the handpiece assembly.

In some embodiments, a tip comprising a skirt portion is configured to couple to a handpiece for treating a target area on a patient's skin. A central body portion is coupled to the skirt portion. A first passage extends through the central body portion and is configured to receive a fluid from the handpiece. At least one second passageway extending through the central body portion and is configured to convey the fluid back into the handpiece. An inner member extends in a generally spiral fashion across at least a portion of a distal face of the central body portion. The inner member defines a channel between the first passage and the at least one second passage. When the tip is placed against the skin, a chamber can be formed by the channel and the person's skin.

In some embodiments, a method of treating a target region on a patient's skin comprises providing a tip including a first aperture and at least one second aperture. At least one inner member on the surface of the tip defines at least one channel between the first aperture and the at least one second aperture. An outer member is disposed on the surface of the tip. The outer member engages the target with the tip. A treatment fluid flows distally through the first aperture region and through the at least one channel. The treatment fluid flows proximally through the at least one second aperture.

In some embodiments, a tip comprises a skirt portion configured to couple to a handpiece for treating a target on a patient's skin. A central body portion is coupled to the skirt portion and includes a mounting region substantially oppo-

3

site the skirt portion. The mounting region configured to receive a pad for treating the skin. A first aperture extends through the skirt portion and the central body portion and configured to receive a fluid from the handpiece. At least one second aperture extending through the skirt portion and the central body portion and configured to convey the fluid back into the handpiece.

In some embodiments, a method of treating a target region of a patient comprises providing a tip including a first aperture, at least one second aperture, and a distal end configured to receive a pad. In some variations, the first pad is attached to the distal end. The tip is engaged with the target region.

In some embodiments, a manifold system comprises a body portion configured to receive releasably at least two bottles. The manifold is configured so that it can be coupled to a console. The console includes a handpiece for treating skin. At least one elongate member is in communication with a pump and configured to extract a fluid from one of the at least two bottles. At least one switch is configured to permit or inhibit a flow of the fluid from one of the at least two bottles through the pump. In some variations, the elongate member is dimensioned to fit within one of at least two bottles to draw fluid out of the bottle.

In some embodiments, a method of treating a target region on a patient's skin comprises engaging a tip with the patient's skin such that an effective amount of skin is removed by the tip. In some variations, the tip is a dry tip. After removing an effective amount of skin, another tip (e.g., a wet tip) engages the patient's skin such that an effective amount of skin is removed by the tip. In some variations, acid is delivered out of the wet tip to facilitate skin removal. In some variations, the wet tip includes a first aperture, at least one second aperture, at least one inner member on the surface of the tip defining at least one channel between the first aperture and the at least one second aperture, and an outer member on the surface of the tip. In some variations, treatment fluid flows outwardly along the channel. In some variations, treatment fluid flows inwardly along the channel. In some variations, the wet tip comprises an abrasive pad.

In some embodiments, a method of treating a target region on a patient's skin comprises engaging a first skin treatment tip with the patient's skin. A first material is delivered out of the first skin treatment tip to a target region. A second skin treatment tip engages the target region while the first material effectively facilitates exfoliation with the second skin treatment tip. In some variations, the first material comprises an acid, hydrator, and combination thereof. In some variations, the first skin treatment tip is configured to remove skin at a different rate than the second skin treatment tip. In some variations, the first skin treatment tip is configured to exfoliate at a higher rate than the second skin treatment tip. In some variations, material is delivered out of the second treatment tip to the target region of the patient's skin.

The apparatus for treating skin can dispense treatment material that is held in containers, such as bottles, bags, pouches, or other suitable structures for holding and storing material. These containers can be non-refillable or refillable. The treatment material can be delivered by gravity feed, pumps, or suction devices. The manifold system can be used to control fluid flow from a plurality of containers to one or more handpieces.

BRIEF DESCRIPTION OF THE DRAWINGS

Having thus summarized the general nature of the invention, certain preferred embodiments and modifications

4

thereof will become apparent to those skilled in the art from the detailed description herein having reference to the figures that follow.

FIG. 1 is a perspective view of one embodiment of a skin treatment system.

FIG. 2A is a perspective view of one embodiment of a handpiece assembly for use with the skin treatment system of FIG. 1.

FIG. 2B is a side elevational view of the handpiece assembly of FIG. 2A.

FIG. 3 is a longitudinal cross-sectional view of the handpiece assembly of FIG. 2B. The handpiece assembly is engaging a person's skin.

FIG. 4 is a perspective view of another embodiment of a handpiece assembly.

FIG. 5A is a perspective view of one embodiment of a tip that can be coupled to a main body of a handpiece assembly to treat a person's skin.

FIG. 5B is a top elevational view of the tip of FIG. 5A.

FIG. 5C illustrates a bottom elevational view of the tip of FIG. 5A.

FIG. 5D is a cross-sectional view of the tip of FIG. 5B taken along the line 5D-5D.

FIG. 6A is a perspective view of a tip in accordance with another embodiment.

FIG. 6B is a top elevational view of the tip of FIG. 6A.

FIG. 6C is a bottom elevational view of the tip of FIG. 6A.

FIG. 6D is a cross-sectional view of the tip of FIG. 6B taken along the line 6D-6D.

FIG. 7A is a perspective view of a tip in accordance with another embodiment.

FIG. 7B is a top elevational view of the tip of FIG. 7A.

FIG. 7C is a bottom elevational view of the tip of FIG. 7A.

FIG. 7D is a cross-sectional view of the tip of FIG. 7B taken along the line 7D-7D.

FIG. 8A is a perspective view of yet another embodiment of a tip for treating a person's skin.

FIG. 8B is a top elevational view of the tip of FIG. 8A.

FIG. 8C is a bottom elevational view of the tip of FIG. 8A.

FIG. 8D is a cross-sectional view of the tip of FIG. 8B taken along the line 8D-8D.

FIG. 9A is a perspective view of still another embodiment of a tip that can be coupled to a main body of a handpiece assembly.

FIG. 9B is a top elevational view of the tip of FIG. 9A.

FIG. 9C is a bottom elevational view of the tip of FIG. 9A.

FIG. 9D is a cross-sectional view of the tip of FIG. 9B taken along the line 9D-9D.

FIG. 10A is a perspective view of another embodiment of a tip for treating a person's skin.

FIG. 10B is top elevational view of the tip of FIG. 10A.

FIG. 10C is bottom elevational view of the tip of FIG. 10A.

FIG. 10D is a cross-sectional view of the tip of FIG. 10B taken along the line 10D-10D.

FIG. 10E is a perspective exploded view of the tip of FIG. 10A, wherein a pad is spaced from a tip main body.

FIGS. 11A-11E are cross-sectional views of inner members that can be used to exfoliate skin.

FIG. 12 is a perspective view of a bottle for use with the skin treatment system of FIG. 1.

FIG. 13A is a cross-sectional view of one embodiment of a bottle spaced from an insertion tip assembly.

FIG. 13B is a cross-sectional view of the bottle of FIG. 12A coupled with the insertion tip assembly.

FIG. 14A is a cross-sectional view of a closure and a bottle.

5

FIG. 14B is a cross-sectional view of the closure and bottle of FIG. 14A when assembled.

FIG. 15A is a perspective view of one embodiment of a manifold system holding a plurality of bottles.

FIG. 15B is a cross-sectional view of the manifold system of FIG. 15A taken along the line 15B-15B of FIG. 15A.

FIG. 15C is a cross-sectional view of the manifold system of FIG. 15A taken along the line 15C-15C of FIG. 15A.

FIG. 15D is a cross-sectional view of the manifold system of FIG. 15C wherein the bottle has been removed.

FIG. 15E is a cross-sectional elevational view of the manifold system.

FIG. 16 is a perspective view of another embodiment of a skin treatment system.

FIG. 17 is a cross-sectional view of a fluid line of the skin treatment system of FIG. 16 taken along the line 17-17.

FIG. 18 is a side elevational view of a handpiece assembly with a removable cartridge.

FIG. 19 is a side elevational view of the handpiece assembly and removable cartridge of FIG. 18, the cartridge is shown removed from the handpiece assembly.

DETAILED DESCRIPTION

FIG. 1 illustrates a skin treatment system 10 that can be used to perform one or more treatments on a person's skin. The illustrated skin treatment system 10 includes a console 12 and a handpiece assembly 18 connected to the console 12 via a line 20. A manifold system 24 can control the flow of treatment material from containers 26 into and through the line 20. The treatment material can be discharged out of the handpiece assembly 18 to treat a person's skin. The skin treatment system 10 can be used at a hospital, health care physicality, residences, or any other suitable location.

As explained in more detail below, the handpiece assembly 18 is applied to the target area of the patient to perform skin treatment(s). As used herein, the term "skin treatment" is a broad term and includes, but is not limited to, skin removal, skin abrasion (e.g., dermabrasion, microdermabrasion, etc.), ablating or slicing skin (preferably a thin layer of skin), stimulation (including thermal, mechanical, electrical, and/or chemical stimulation), mesotherapy, isophoresis, light therapy, vacuum therapy, and the like. Preferably, the handpiece assembly 18 administers a treatment material from at least one of the containers 26 through the line 20 to the target area of the skin while the handpiece assembly 18 engages the skin.

As used herein, the term "treatment material" is a broad term and includes, but is not limited to, medicament, a substance tending to flow or conform to the outline of its container such as fluid, gas, liquid (e.g., serums, water, saline, etc.), gel, fluidized material, additives, and/or a plurality of fine solids. The general term "fluid" is used throughout synonymously with the term "treatment material" and is to be given the same broad definition. The handpiece assembly 18 can preferably massage, abrade, ablate, or otherwise treat the target skin area while also applying a treatment material to the patient. In certain embodiments, the treatment material and tip of the handpiece 18 can work in combination for an effective and rapid skin treatment. Additionally, any number of "dry" and "wet" tips can be used alone or in combination for treatment flexibility.

With continued reference to FIG. 1 the line 20 is configured to provide fluid communication between the containers 26 and the handpiece assembly 18. The line 20 can comprise one or more conduits extending between the console 12 and

6

the handpiece assembly 18. In certain embodiments, the line 20 includes a supply line and a waste line for delivering and returning material, respectively, as detailed below.

The distal end 22 of the line 20 is connected to the handpiece assembly 18. Preferably, the line 20 includes a filter 28 that removes contaminants or impurities from the treatment material passing through the line 20. In other embodiments, the filter 28 is located in the console 12 or the manifold system 24. The console 12 can be connected to a power source such as an AC outlet. The power source can power the handpiece assembly 18 and/or other components of the skin treatment system 10, such as, for example, pumps, valves, and the like.

In the illustrated embodiment, the console 12 comprises four casters 33 to allow for easy movement, for example, from one treatment room to another treatment room. In such an embodiment, the console 12 can be conveniently rolled on a support surface. Other means of transportation can also be employed or the console 12 can be stationary. In some embodiments, the console 12 is portable for convenient transport.

The illustrated containers 26 of FIG. 1 are preferably releasably coupled to the manifold system 24. The manifold system 24 can deliver treatment material from the containers 26 to the line 20 as mentioned above. In certain embodiments, the console 12 has a user input device 32 for selecting a treatment material to be passed through the line 20 to the handpiece assembly 18. During some skin treatment procedures, treatment materials from multiple containers 26 are sequentially or simultaneously applied to the patient's skin during a "wet" mode of operation. Alternatively, the skin treatment system 10 can be used to deliver a single treatment material to the patient's skin. In some embodiments, the console 12 can be used for a "dry" mode of operation. That is, the console 12 can be used to exfoliate skin, for example, without delivering little or substantially no treatment fluid. The skin treatment system 10 can thus provide flexibility in selecting a treatment plan.

Multiple handpieces assemblies 18 and/or tips 34 can be used during a single skin treatment procedure in a wet and/or dry mode of operation. For example, a first handpiece assembly 18 may be employed to treat a patient's face and neck while a second handpiece assembly 18 may be employed to treat other larger areas of the patient's body. Thus, different handpieces 18 can be used to treat different regions of a person's body. The configurations of the handpieces 18 and tips can be selected based on the treatment material to be applied, desired interaction with the patient's skin, size of treatment area, skin condition, and the like.

With reference to FIGS. 2A and 2B, the handpiece assembly 18 includes a main body 30 and a tip 34. The handpiece assembly 18 can be conveniently held within the hand of a user so that the user can place the tip 34 in operative engagement with a person's skin. The user is typically an aesthetician (e.g., an aesthetician allowed to perform microdermabrasion), doctor, and other medical personnel, such as a physician assistant and nurse practitioner. In some cases, the user is the person whose skin is being treated.

The main body 30 has contoured portions 70 at its distal end 36 so that the user can comfortably grip the handpiece assembly 18 during use. The main body 30 can have other designs to provide a comfortable grip. FIG. 2A illustrates an embodiment in which the main body 30 is substantially flat on two opposing sides. FIG. 4 illustrates an embodiment in which the main body 30 is generally cylindrical.

As noted above, the tip 34 can be pressed against a patient's skin to perform a skin treatment. The distal end 102

7

of the tip 34 may be angled with respect to the handpiece assembly 18 to increase the contact area with the patient's skin without enlarging the handpiece assembly 18 for an ergonomic and comfortable design. The angled tip 34 can lay flat on the skin while the main body 30 is angled to the skin. The angle between the face of the distal end 102 and the longitudinal axis of the handpiece assembly 18 can be selected based on the desired size of the face of the distal end 102. In alternative embodiments, the face of the distal end 102 is generally perpendicular to the longitudinal axis of the main body 30.

The tip 34 can be permanently or temporarily coupled to the distal end 36 of the main body 30. In some embodiments, the tip 34 is disposable. As used herein, the term "disposable," when applied to a system or component (or combination of components), such as a tip, container, or pad, is a broad term and means, without limitation, that the component in question is used a finite number of times and then discarded. Some disposable components are used only once and then discarded. Other disposable components are used more than once and then discarded. In some embodiments, the tip 34 is removably coupled to the main body 30 such that the tip may be removed from the main body 30 and thrown away to avoid cross-contamination. In other embodiments, the tip 34 is a reusable tip that can be cleaned, for example by autoclaving, after each use. The tip 34 can thus be used for any number of procedures as desired.

With reference to FIGS. 2A and 2B, the proximal end 40 of the main body 30 is operatively connected to the line 20. In the embodiment illustrated, the line 20 includes an output line 50 for removing waste from the handpiece assembly 18 and an input line 52 for delivering treatment material to the handpiece assembly 18. The proximal end 40 of the main body 30 includes a plurality of connectors 44, 46, each connected to one of the conduits 50, 52. The illustrated input line 52 is connected to the connector 46, and the output line 50 is connected to the connector 44.

The input line 52 delivers treatment material from at least one of the containers 26 to the connector 46. The fluid then flows through the main body 30 and ultimately to the tip 34. As shown in FIG. 3, the main body 30 comprises a plurality of lumens 90, 92 in a fluid communication with the tip 34. Fluid from the input line 52 can flow through the input lumen 92 to the tip 34. The fluid then flows out of the tip 34 to a target skin area. The fluid is then trapped in the space 100 between the skin 80 and the tip 34. To remove the fluid, the fluid flows proximally through the lumen 90 to the output line 50. The fluid passes through the output line 50 and into the console 12. As such, fluid can continuously or intermittently flow through the handpiece assembly 18.

To treat the person's skin 80, the handpiece assembly 18 can also be moved relative to the skin 80 such that the tip 34 maintains engagement with the skin 80. The illustrated tip 34 is configured to massage the skin 80 while also providing fluid communication with the skin 80. As detailed below in connection with FIGS. 5A through 10, the tip can include sharp planing blades, blades (e.g., razor blades), raised sharp areas, molded posts, grits, or other structures for treating skin, as detailed below.

When the tip 34 and treatment material are used in combination, the handpiece assembly 18 preferably exfoliates dead skin cells and extracts impurities by applying a vacuum while simultaneously bathing the healthy underlying skin with active treatment material. The active treatment material can facilitate cleansing, exfoliating, hydrating, and/or provide residual antioxidant protection. The treatment material and tip 34, alone or in combination, can effectively

8

and rapidly treat the target skin area. The waste material, including the used treatment material, removed skin, and/or grit, can then be drawn back through the tip 34, the main body 30 via lumen 90, and into the connector 44. The waste then flows into the output line 50 for subsequent disposal, as detailed below in connection with FIG. 4.

In some embodiments, including the illustrated embodiment of FIG. 3, the tip 34 has a tip connector 98 (see FIGS. 5C and 5D) that mates with the lumen 92. The tip 34 can provide fluid communication from the tip connector 98 to the space 100 via a through-hole 122. One or more through-holes 114 define fluid passageways through the tip 34 between the space 100 and the intermediate chamber 116.

The intermediate chamber 116 can be interposed between the through-holes 114 and the lumen 90. The intermediate chamber 116 is preferably defined by the distal face 43 of the main body 30 and the proximal face 41 of the tip 34. The intermediate chamber 116 can provide equalization of fluid between the tip 34 and the body 30. As such, a generally equal vacuum is applied to both through-holes 114. The fluid can flow through the through-holes 114, into the intermediate chamber 116, and then into the lumen 90. In some embodiments, however, the fluid flows directly from the through-holes 114 to the lumen 90 without passing through an intermediate chamber 116.

The tip 34 can have one or more sealing members to form a fluidic seal between the tip 34 and the main body 30. The illustrated main body 30 includes a sealing member 47 that engages the inner surface of the skirt 64 of the tip 34. The sealing member 47 can be a compliant member comprising rubber, polymer, plastic, or other suitable material for forming seals. In some embodiments, the sealing member 47 is an O-ring made of rubber.

With continued reference to FIG. 3, during use, treatment material can flow distally through the lumen 92 into the through-hole 122. The treatment material then proceeds through and out of the through-hole 122 into the space 180. Preferably, the treatment material spreads radially outward to the peripheral through-holes 114. The material can then flow through the through-holes 114 into the lumen 90 for subsequent removal.

In alternative embodiments, the fluid flows in the opposite direction. That is, the line 50 delivers fluid through the lumen 90 into the tip 34. The fluid flows through the intermediate chamber 116 and the through-holes 114. The fluid then flows to the chamber 100 and inwardly through the tip connector 98 to the lumen 92. The fluid proceeds proximally along the lumen 92 and ultimately into the line 52.

In yet another embodiment, the handpiece assembly 18 comprises two or more input lumens 90. Such a design allows mixing of two or more treatment materials within the handpiece assembly 18 or space 100, which would be useful for treatments with fluids that react or are unstable or degrade when stored or mixed.

As depicted in FIG. 4, the handpiece assembly 18 can optionally include a controller 60 that is configured to control the fluid flow out of the tip 34. The illustrated controller 60 can be operated to increase or decrease the flow rate of treatment fluid out of the tip 34. Alternatively or additionally, the controller 60 may control the flow rate of waste fluid flowing through the handpiece assembly 18 to the output line 50. When control of the waste treatment fluid and waste fluid is independent, the detention time of the fluid in the tip 34 may be adjusted as desired.

The illustrated controller 60 is a generally cylindrical body that is pivotally connected to the main body 30. FIG.

4 illustrates an embodiment in which the controller 60 is recessed into and partially hidden by the main body 30, although in other embodiments the controller 60 may encircle the main body 30. The controller 60 may include textured grooves to provide for easier manipulation. In some embodiments, the controller 60 is located near the distal end 36 of the handpiece assembly 18 proximal or distal of the contoured portion 70. The type and configuration of the controller 60 can be selected based on the design of the handpiece assembly 18. The controller 60 can also be a

rotatable knob or handle, digital controller, and the like. The handpiece assembly 18 can also include one or more flow rate controllers within the main body 30 that cooperate with the controller 60 to adjust the fluid flow out of the tip 34. For example, the controller 60 may comprise a flow control valve such as a globe valve, butterfly valve, needle valve, or variable orifice. Other types of flow rate controllers can also be used, such as an electrically controlled solenoid valve. In embodiments where the fluid flow is electronically controlled, the valve system may alternatively be located in the console 12 or manifold system 24. Separate devices can also be used to control the flow of treatment material. For example, clamps, pinch valves, or other suitable devices can be used to control fluid flow through the lines 50, 52.

Various types of tips 34 can be used with the handpiece assemblies 18 illustrated in FIGS. 1 to 4. FIGS. 5A through 10E illustrate embodiments, for example, of tips 34 that can be used with these handpiece assemblies 18. These tips 34 can be interchangeable to provide maximum treatment flexibility.

As shown in FIGS. 5A through 10E, the tip 34 comprises the skirt 64 and a tip main body 66 extending outwardly therefrom. The skirt 64 is preferably configured to provide a gripping surface suitable for applying leverage or force sufficient to remove the tip 34 from the main body 30. In some embodiments, the skirt 64 includes internal threads such that it can be mechanically coupled to external threads on the distal end 36 of the main body 30. In some embodiments, the tip 34 can be press fit onto the main body 30. Frictional forces can retain the tip 34 to the main body 30.

With respect to FIGS. 5A through 7, the tip 34 comprises an outer member 120 and an inner member 124. The outer member 120 preferably defines the periphery of the distal end 102 of the tip 34. When the tip 34 is placed against skin, the outer member 120 can inhibit fluid flow between the tip 34 and the skin and define the outer portion of the space 100.

The inner member 124 is preferably spaced from the outer member 120 to define one or more channels. The illustrated outer member 120 defines a continuous channel 140 that extends outwardly from the central through-hole 122 towards at least one of the outer through-holes 114. The inner member 120 can form the sidewalls of the channel 140. Any suitable configuration of channels 140 can be used to provide fluid flow along a flow path. The illustrated channels 140 have a somewhat U-shaped axial cross-sectional profile, as depicted in FIG. 8A. The channel 140 can have a V-shaped, curved, or any other suitable cross sectional profile. A flow path between the through-holes in the tip 34 can be defined at least in part by the channels.

The spiral-like pattern of the inner members 124 in FIGS. 5 through 7 varies. For example, the inner member 124 in FIG. 5 extends about a longitudinal axis 143 of the tip 34 approximately one and a half times, the inner member 124 in FIG. 6 extends about the tip 34 approximately two and a half times, and the inner member 124 in FIG. 7 rotates about the tip 34 approximately one and three quarters times. In some embodiments, the inner member 124 subtends an

angle of about 70°, 135°, 180°, 210°, 225°, 270°, 315°, 360°, and angles encompassing such ranges. In yet other embodiments, the inner member 124 subtends an angle of about 405°, 450°, or 495°. The tightness of the spiral in combination with the location and number of through-holes 114 affects the detention time of the fluid in the channel 140. Generally, a tighter spiral results in a longer the pathway (i.e., the length of the channel 140) from delivery through-hole 122 to the return through-holes 114. Fluid traveling down the longer pathway is in contact with the person's skin 80 for a longer period of time. Thus, tighter spirals lead to increased contact time between the fluid and the skin 80. These longer contact times can increase the effectiveness of the fluid because the skin can absorb an adequate amount of active ingredients of the treatment material. Fluid retention time on the patient's skin can be increased to increase hydration, serum retention, and the like. Shorter pathways can be used to reduce contact time between the fluid and the patient's skin. In some embodiments, for example, the tip 34 of FIGS. 5A to 5D has a relatively short pathway to limit absorption of fluids, achieve relatively high flow rates, and the like.

Additionally, the inner members 124 can be configured to remove tissue. The inner member 124 can be an abrasive member designed to remove tissue when the inner member 124 slides along a person's skin. The user may select a tip 34 based on the appropriate detention time and abrasiveness for the treatment being applied. For example, the tip 34 illustrated in FIG. 7 will provide less abrasion than the tip 34 illustrated in FIG. 6, but the tip 34 illustrated in FIG. 7 will provide a longer detention time than the tip 34 illustrated in FIG. 5.

The illustrated tip 34 includes a generally continuous inner member 124 that extends from near the through-hole 122 towards at least one of the through-holes 114. In other embodiments, the tip 34 can have a plurality of inner members 124. For example, the inner members 124 can be linear, curved, and may be continuous or discontinuous.

The handpiece assembly 18 can be moved while the spiral-like inner member 124 engages the patient's skin. The movement of the handpiece assembly 18 can increase the effectiveness of the treatment material expelled out of the tip 34. In some embodiments, for example, the tip 34 can be used with a lifting treatment material that facilitates extractions of, for example, sebum, blackheads, skin, or other substances (e.g., oils, dead skin, etc.). The lifting treatment extraction producer can unclog pores to improve the treated skin's overall appearance. To facilitate extractions, the handpiece assembly 18 can be twisted or rotated while the tip 34 is pressed against the patient's skin. The twisting action and the lifting treatment material can work in combination for effective extractions. In alternative embodiments, a handpiece assembly 18 can also be used without a lifting treatment material for extractions by employing the twisting motion.

In certain embodiments, the spiral-like tip 34 massages the skin 80. In other embodiments, the spiral-like tip 34 ablates the skin 80. For example, the inner members 124 may act as blades to cut thin layers from the skin 80 when the user twists the handpiece assembly 18. Twisting the handpiece assembly 18 causes the tip 34 to rotate about the twisting axis, rotating the sharp inner members 124 against the skin 80, which causes ablation. Thin layers of skin can thus be removed by the handpiece assembly 18. Additionally or alternatively, the spiral-like tip 34 may plane along skin when a fluid is applied to the skin. The planing tip 34 can remove a thin layer of the skin (e.g., the stratum corneum,

11

preferably hydrated stratum corneum). Accordingly, the user can use the handpiece assembly 18 to remove a particular amount of skin.

A vacuum can be applied by the handpiece assembly 18. For example, the console 12 can have a pump that applies a vacuum via the output line 52. The negative pressure draws waste material into the through-holes 114 and out of the handpiece assembly 18. When the tip 34 engages the patient's skin, the vacuum can draw the skin against the tip 34 to enhance the effectiveness of the inner members 124. The vacuum can be increased or decreased to increase or decrease, respectively, for example, frictional forces, depth of cutting, amount of abrasion, and the like. To rapidly remove skin, a strong vacuum can be applied to the person's skin so that the skin is pulled against the inner member 124. The vacuum can also facilitate removal of the waste fluid captured between the tip 34 and the patient's skin. A vacuum can also be used in combination with the tips illustrated in FIGS. 1-10E. The vacuum can also be varied based on the thickness, compliance, and other properties of the skin surface

The tip 34 can have any suitable number of through-holes 114, 122 to achieve the desired fluid flow between the skin 80 and the tip 34. For example, FIG. 5A to 5D illustrate an embodiment with two through-holes 114. The number of through-holes 114, 122 can be chosen based on the cross-sectional areas of the through-holes 114, 122 and the expected flow rate of the fluid through the channel 100. Preferably, one end of through-holes 114 is positioned between the inner member 124 and the outer member 120. In some embodiments, including the embodiments illustrated in FIGS. 5A through 7, the through-holes 114 are positioned generally midway between the outer member 120 and inner member 124.

The tips can also have one or more energy sources for delivering energy to the skin. Radiant energy, heat, and the like can be delivered to the skin by the tips. The tip 34 illustrated in FIGS. 6A to 6D has a pair of energy sources 151 in the form of LEDs. When the tip 34 is proximate the patient's skin, the LEDs 151 can deliver a desired amount of energy to the skin. The illustrated tip 34 has four LEDs; however, any number of LEDs can be employed.

In alternative embodiments, the tips can carry deployable material. The structure 151 can be in the form of a cavity or pocket that contain and carry material that is released when it engages the treatment fluid. The material in the cavities 151 can be made of any of the treatment materials disclosed herein, and can be in a solid form. For example, the cavities can hold lubricant or soap that is released when the tip is applied to skin.

FIGS. 8A through 8D illustrate another embodiment of a tip 34 when the inner member 124 includes a ring with perforations 140 that provide fluid communication between the through-hole 122 and through-holes 114. A space 100 can be defined between the inner member 124, perforations 140, and outer member 120 when the tip 34 is in operative engagement with the skin 80. FIG. 8C illustrates an embodiment with eight through-holes 114. In the embodiment illustrated in FIGS. 8A through 8D, the inner member 124 forms recessed regions 171, allowing for a larger area of fluid contact with the skin 80 than the tips 34 illustrated in FIGS. 5 through 7.

FIGS. 9A through 9D illustrate another embodiment of a tip 34 comprising an outer member 120 and an array of protruding inner members 124. A recessed region 191 is defined between the inner members 124 and the outer member 120. The inner members 124 of FIGS. 9A to 9D can

12

be posts that are similar to the inner members described above. The post 124, for example, can have relatively sharp edges. These edges can be used to remove skin. In some embodiments, the inner members 124 can have relatively sharp planing blades. The tip 34 illustrated in FIGS. 9A through 9D allows for more freedom of movement of the treatment fluid. The protruding inner members 124 preferably abrade the skin differently than the tips 34 illustrated in FIGS. 5A through 8. Rather than being able to ablate large sections of the skin 80 like a blade, as the tips 34 in FIGS. 5A-8 can do in certain embodiments, the plurality of protruding inner members 124 can ablate or roughen a plurality of smaller sections of the skin 80.

The protruding member 124 can optionally contain treatment material. For example, the protruding members 124 can be generally cylindrical members having a passageway or chamber 127 that holds treatment material. Thus, fluid can be used in combination with treatment material coupled to the tip 34.

With reference to FIGS. 5A through 9, the inner member 124 preferably has a height from the distal surface that is generally less than the height of the outer member 120. In some non-limiting embodiments, the height of the inner member 124 is less than 90%, 70%, 60%, 50%, and ranges encompassing such percentages of the height of the outer member 120. However, in other embodiments, the inner member 124 has a height that is generally greater than the height of the outer member 120. For example, the inner member 124 can have a height that is 10%, 20%, 30%, 40%, 50% greater than the height of the outer member 120. The inner member 124 can thus protrude from the tip 34. A skilled artisan can select a desired height of the inner member 124 and/or the outer member 120 to achieve the desired interaction with the person's skin 80.

FIGS. 10A through 10E illustrate another embodiment of a tip 34 comprising an outer member 120 and a pad 128. FIG. 10E depicts the pad 128 removed from the tip 34. The tip 34 preferably has a mounting surface 227 that is surrounded by the outer member 120. The pad 128 can be permanently or temporarily coupled to the mounting surface 227.

The pad 128 preferably has a distal surface 224 configured to treat a person's skin. In some embodiments, the pad 128 is a disposable pad that comprises treatment material attached thereto. For example, the pad 128 may comprise vitamins, moisturizers, antioxidants, and the like. Preferably, the pad 128 comprises an adhesive proximal side and a distal side 224 including an abrasive surface. The abrasive surface can have grit, a plurality of members (e.g., members similar to the inner members 124 described above), or the like. The pad 128 can be permanently coupled to the mating surface 227 so that the tip 34 can be used for an extended length of time, or for multiple treatments. In alternative embodiments, the tip 34 is removable for maximum flexibility in selecting pad abrasiveness, and also allows the user to make changes to the tip 34 without changing the tip 34 in its entirety. The grit rating of abrasive surface of the distal surface 224 can be selected based on the desired rate of skin removal.

The illustrated pad 128 is generally elliptical and planar. In alternative embodiments, the pad 128 can be polygonal, circular, or have any other shape as desired. The pad 128 can have cutouts 225 that can match the through-holes 114, 122. The cutouts 225 can be aligned with the through-holes 114, 122 when the pad 128 is coupled to the mounting surface 227 of the tip 34, as shown in FIGS. 10A to 10D. The illustrated mounting surface 227 defines a plurality of tip flow channels 229 extending between the through-holes 114,

13

122. When the tip 34 is assembled, fluid can flow along the channels 229 between the main body 66 and the pad 128.

Various types of adhesives can be used to temporarily or permanently couple the pad 128 to the mounting surface 227. As used herein, the term “adhesive” is a broad term and includes, but is not limited to, coupling agents, glues, bonding materials, or the like. In some embodiments, for example, waterproof pressure sensitive adhesives are used for releasably coupling the pad 128 to the mounting surface 227. In some embodiments, the pad 128 can be permanently coupled to the mounting surface 227. For example, the pad 128 can be bonded or fused to the main body 66. Additionally or alternatively, snap fittings, fasteners, or other coupling structures can be used to mount the pad 128.

The tip 34 described above can be used for wet or dry modes of operation. As such, the tip 34 can be used for wet exfoliation or dry exfoliation. In some embodiments, the tip 34 is used in a dry mode to remove a desired amount of skin. After removing a desired amount of skin, the tip 34 can be used in a wet mode on the same or different area of the patient's skin. During wet mode, fluid can be passed out of the tip 34 onto the patient's skin. The wet tip 34 can exfoliate, hydrate, and/or perform other types of treatments. Alternatively, the tip 34 can be used in a wet mode and then a dry mode. The sequence of wet and dry modes of operation can be selected based on the type of tip, treatment material, skin condition, and the like.

Although the handpiece assemblies are primarily discussed with respect to use with treatment material, the handpiece assemblies can be used without treatment material, i.e., the handpieces can be used in a dry procedure. Dry procedures can be used for non-hydration procedures and may require less post-procedure clean up.

Various fabrication techniques can be employed to make the tips 34 as mentioned above in connection with FIGS. 11A-11E. In some embodiments, the tips 34 are formed through a molding process, such as an injection or compression molding process. The tips 34 of FIGS. 5A to 5D, for example, can be monolithically formed through an injection molding process. Alternatively, the tip 34 of can have a multi-piece construction, if desired. The tips 34 can be made of polymers, rubbers, metals, or other suitable materials.

The tips 34 can also be fabricated in a multi-step process. For example, the main body 66 and skirt 64 can be formed in a single process. A textured surface (e.g., pad, inner members 124, etc.) can be applied to the main body 66 in a subsequent process. The textured surface can be formed by cutting, embossing, adding material (e.g., a pad, adhesive grit, etc.), a roughening implement, stamping process, or other suitable texturing means.

The tips can have associated treatment materials, including, for example, a medicament. As used herein, the term “medicament” is a broad term and includes, without limitation, growth agents, growth factors or hormones, growth inhibitors, serums, treatment material, cleaners, vitamins, exfoliators, lubricants, or other substances that can be used to treat a patient's skin. The medicament can be associated with the tip 34 by imbedding, overlaying, coating, impregnation, co-mixing, absorption, or other suitable means for associating the medicament with the tip 34. The medicament can be hardened so that it can further enhance massaging and/or abrasion. In some embodiments, the medicament forms hardened grit that can be imbedded on the surface of the tip 34. The grit can work in combination with the inner members 124 to treat a person's skin. If a fluid is used, the fluid can facilitate the release of the medicament from the tip 34. In some embodiments, the medicament comprises or

14

more bioactive substances, such as antibiotics, substances for accelerating the healing of the wound, cell proliferation agents, and the like. Such bioactive substances may be desirable because they contribute to the healing of damaged or removed skin, as well as reducing the likelihood of infection.

FIGS. 11A to 11E illustrate different cross-sections of inner members that can be used with the tips illustrated in FIGS. 1-10E. The inner member 124 of FIG. 11A has generally sharp tip 253 for removing tissue. The tip 253 can have any suitable configuration for removing tissue from a patient. FIG. 11B illustrates an inner member 124 that has a pair of cutting edges 253 and a generally trapezoidal shape. FIG. 11C illustrates an inner member 124 that has a surface treatment 255 for treating a person's skin. The surface treatment 255 can be serrations, grooves, grit, roughed surface, protrusions, and the like. The type of surface treatment 255 can be selected based on the procedure to be performed. FIG. 11D illustrates another inner member 124 having a pair of cutting edges 253. The cutting edges 253 are spaced from each other and protrude outwardly. The central portion 257 is generally V-shaped; however, the central portion 257 can have other configurations. For example, FIG. 11E illustrates a central portion 257 that has a curved, semi-circular profile. In alternative embodiments, the inner member 124 can have more than two cutting edges.

The inner members 124 of FIGS. 11A to 11E can be formed by a molding process, such as an injection molding process. Additionally or alternatively, the inner members 124 can be formed by a machining process. For example, at least a portion of the inner member 124 of FIGS. 11D to 11E can be formed through a machining process. In some embodiments, the central portion 257 can be formed by cutting material out of the inner member 124. The fabrication process (e.g., molding, injection molding, compression molding, machining, milling, etc.) can be selected based on the design of the inner members.

Referring again to FIG. 1, the console 12 includes a manifold system 24 that holds containers 26 containing treatment fluids and/or antimicrobial agents. In a preferred embodiment, the console 12 holds four containers 26, three containing different treatment fluids and one containing an antimicrobial agent. In the illustrated embodiment, the largest container 26 holds antimicrobial agent for cleaning and sanitizing the fluid lines of the console 12. The containers 26 can also hold other suitable substances, such as surfactants, disinfectants, sanitizers, and the like, for cleaning and/or sanitizing the skin treatment system 10.

As shown in FIGS. 12 and 12A, the container 26 can be a fluid source such as a bottle comprising a body 262, a neck 264, and a closure assembly 266. The neck 264 includes a threaded neck finish and the closure 266 includes a threaded interior surface, allowing it to screw onto the neck 264. The closure 266 can be permanently or temporarily coupled to the neck 264. The illustrated bottle 26 is a non-refillable, disposable bottle. As used herein, the term “non-refillable” is a broad term that includes, but is not limited to, components that cannot be easily refilled with a treatment material. For example, the illustrated non-refillable bottle 26 cannot be refilled without substantial difficulty.

Bodies 262 of the containers 26 may be formed by stretch blow molding a preform into the desired shape. In other embodiments, the body 262 and a neck 264 can be formed by extrusion blow molding. For example, the bottle of FIG. 13A can be formed by extrusion blow molding. The containers 26 can be made of polymers, thermosets, thermoplastic materials such as polyesters (e.g., polyethylene tere-

15

phthalate (PET)), polyolefins, including polypropylene and polyethylene, polycarbonate, polyamides including nylons, epoxies, and/or acrylics. The material can be virgin or post-consumer/recycled. However, other suitable materials known in the art can also be used.

In some embodiments, including the illustrated embodiment of FIGS. 12 and 12B, the closure 266 is welded (e.g., induction welded) to an upper edge 269 of the neck 264. A sealing member 267 can be interposed between the upper edge of the neck 269 and the closure 266. In some embodiments, the sealing member 267 is made out of a conductive metal, such as aluminum, that preferably does not react with the fluid in the bottle 26. In other embodiments, the seal 267 comprises plastic, such as cellophane, polypropylene, or other suitable material, preferably suitable for coupling to the closure 266 and upper edge 269. In some embodiments, the sealing member 267 comprises metal that is at least partially coated with a polymer, such as polypropylene. Induction welding can be used to couple the polypropylene to the closure 266 and neck 264, both of which can also comprise polypropylene.

FIG. 14A illustrates another embodiment of a bottle 26. The closure 266 includes locking members 268 that engage the neck 264, but do not allow removal of the closure 266 from the bottle 26 when assembled, as shown in FIG. 13B. The locking closure 266 may include a sealing member 267, for example as described above.

In either of the embodiments illustrated in FIGS. 12 through 14B, the closure 266 may then be sealed with a second closure (not shown), creating multi-piece closures. For example, a screw cap can be threaded onto the external threads 273 at the top end of the closure 266. In these embodiments, the treatment fluid inside the bottle 26 may be accessed by puncturing or otherwise breaking the seal 267, for example with an insertion tip assembly 59 (see FIG. 13A).

The insertion tip assembly 59 has an elongate member 161 that comprises a fluid pick up conduit 62 and lancing tip 64 extending from the distal end of the conduit 62. In the illustrated embodiment, the lancing tip 64 is a tubular member having a somewhat sharp distal end. To access treatment fluid in the bottle 26, the lancing tip 64 can be inserted into the closure passageway 73 of the closure 266. The lancing tip 64 can be advanced through the passageway 73 until it breaks the sealing member 267. The elongate member 161 can be sufficiently rigid such that it can break the sealing member 267 without buckling. The elongate member 161 can comprise metal, polymers, plastics, or any suitable material.

The fluid pick up conduit 62 and lancing tip 64 can be slid through the passageway 73 until the stop 91 is spaced from the upper edge of the closure 266. In alternative embodiments, the insertion tip assembly 59 can be slid through the passageway 73 until the stop 91 contacts the upper edge of the closure 266, as shown in FIG. 12B. After the insertion tip assembly 59 and bottle 26 are assembled, as shown in FIG. 12B, the treatment material can be draw upwardly through the lancing tip 64 and the fluid pick up conduit 62. The treatment material can flow through a passageway of the insertion tip assembly 59 and to the manifold assembly 24.

In certain embodiments, the treatment fluid applied from the containers 26 may be selected from the console 12 for a particular treatment or skin type. In one embodiment, the treatment fluid may comprise a skin rejuvenation serum. Skin rejuvenation serum cleans the skin 80 deeply while softening sebum and impurities to aid in extractions. Skin rejuvenation serum also assists in dislodging dead cells for

16

extraction and exfoliation by the tip 34 as well as providing residual hydration that aids in firming and smoothing fine lines, resulting in clean, refined, and ultra-moisturized skin 80. Preferably, a skin rejuvenation treatment serum is active-4™, available from Edge Systems Corp., 2277 Redondo Ave., Signal Hill, CA, 90755, (800) 603-4996. In another embodiment, the treatment fluid may comprise a salicylic acid serum. A salicylic acid serum cleans oily skin deeply while softening sebum and impurities to aid in extraction and exfoliation by the tip 34. Hydration additives in the salicylic acid serum create an ultra-moisturized skin surface, and is blended to remain on the face for the best possible benefit. Preferably, a salicylic acid treatment fluid is beta-hd™, also available from Edge Systems Corp. In yet another embodiment, the treatment fluid may comprise antioxidants. The antioxidant serum is a hybrid that combats free radicals and environmental damage to the cells. The antioxidant serum is formulated with a blend of the most effective antioxidant ingredients. The antioxidant serum is an absorbable, leave-on service that improves the appearance of age signs as well as texture and clarity. Preferably, an antioxidant treatment fluid is antiox-6™ also available from Edge Systems Corp. The treatment fluids may comprise agents known to be beneficial to skin healing and/or hydration including but not limited to glucosamine, *laminaria digitata* extract, yeast extract, carbamide, lactic acid, sodium lactate, honey extract, pentylene glycol, spirea ulmaria extract, *Camellia sinensis* leaf (white tea) extract, horse chestnut extract, stabilized vitamins A, B1, B6, B12, C, and E, tocopherol, inositol, calcium panthothenate, linoleic acid, rosemarinus *officinalis* extract, biotin, and aloins such as anthraquinone glycosides, polysaccharides, sterols, gelonins, and chromones.

A single treatment may comprise the serial use of several treatment fluids from the containers 26. For example, the treatment of acne prone skin may comprise salicylic treatment followed by antioxidant treatment, the treatment of aging skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of congestion (e.g., blackheads) may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of damaged skin (e.g., due to medication or smoking) may comprise skin rejuvenator treatment followed by antioxidant treatment, the treatment of skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of hyperpigmentation may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of melasma may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of sensitive skin may comprise skin rejuvenator treatment followed by antioxidant treatment, and the treatment of thin skin may comprise salicylic treatment followed by antioxidant treatment. Alternatively, a single treatment may comprise the parallel use of a combination of treatment fluids from the containers 26, for example using a handpiece with a plurality of input lumens 90 as described above. Treatment time with each treatment fluid is preferably about 2 to 20 minutes, but may be longer or shorter depending on the patient, the tip 34 used, and the treatment itself.

The treatment materials can be used for acne (e.g., by removing oils, bacteria, etc.), melasma, damaged skin (e.g., sun damaged skin, burns, free radical damage, etc.), extractions, skin lightening and/or brightening, skin lines (e.g., fine lines, wrinkles, creases, etc.), dry skin, and the like. The

17

treatment materials can improve skin elasticity and overall health of the skin. For example, if the skin is damaged, antioxidants can be applied to damaged area. Accordingly, the skin treatment system 10 can be used to improve the health, appearance, and/or function of a person's skin.

Additionally, the line 20 may be periodically flushed with a fluid (e.g., an antimicrobial fluid, water, etc.) contained in one of the containers 26. Antimicrobial fluids can contain any disinfecting agent compatible with skin including, but not limited to, butylene glycol, phenoxyethanol, and methyl isothiazolinone. Preferably, an antimicrobial fluid is Rinseaway™, available from Edge Systems Corp. The line 20 should be flushed with antimicrobial fluid at least at the end of each service day. Flushing with antimicrobial fluid is more important when the system is not used for consecutive days.

As illustrated in FIG. 1, the console 12 comprises the manifold system 24 designed to draw treatment fluid from at least one of the containers 26 based on user selection. The manifold system 24 may include switches 29, each corresponding to one of the bottles. The switches 29 can be used to control fluid flow from the containers 26. The illustrated switches 29 can be used to turn Off/On to permit or prevent fluid flow from the bottles 26. The illustrated manifold system 24 has a switch corresponding to each bottle 26. As such, the switches can be used to independently control fluid flow from each of the bottles 26. In other embodiments, a single switch can be used to control the flow of treatment fluid from more than one of the bottles 26.

With continued reference to FIG. 1, the button 246 can be operated to release a corresponding bottle 26 from the manifold system 24. FIG. 15A is front perspective view an embodiment in which the manifold system 24 contains quick-release locks connected to the button 246, wherein the quick-release locks capture the containers 26. As illustrated in FIGS. 14B and 14C, the quick-release locks 242 engage the closure 266 when the bottle 26 is inserted into the manifold system 24. When the quick-release lock 242 is manually engaged by a user, for example by pulling the button 246, a slide structure 249 surrounding the closure 266 releases, thereby releasing the bottle 26 from the manifold system 24.

FIG. 15E illustrates the slide structure 249 holding the neck 264 of the bottle 26 in an elongated slot 309. The button 246 can be pushed inwardly (indicated by the arrow 313) so that the neck 264 is positioned within the enlarged aperture 317. The bottle 26 can then slide downwardly out of the manifold system 24. The bottle 26 can be replaced with another bottle 26.

To couple the bottle 26 to the manifold system 24, the closure 266 can be inserted through the aperture 317 of the slide structure 249 when the button 246 is pushed in. Once the closure 266 engages the stop surface 333 (FIG. 15C), the spring 247 can push the slide structure 249 until the flange 335 of the bottle 26 rests on the slide structure 249, as shown in FIG. 15C. In such a position, the manifold system 24 securely holds the bottle 26. The illustrated slide structure 249 has a sloped portion 269 that can cam along the flange 335 as the button 246 moves outwardly. Accordingly, the slide member 249 can push the closure 266 upwardly until the closure 266 is locked with the manifold 24, as shown in FIG. 15C. The quick-release lock 242 is loaded with spring 247 such that the slide structure 249 is biased towards the button 246.

The manifold system 24 can have a modular design so that it can be removed from the console 12. In some embodiments, the manifold system 24 and associated containers 26

18

can be removed and transported away from the console 12. Accordingly, the modular manifold systems can be interchanged to provide treatment flexibility. Alternatively, the manifold system 24 can be permanently mounted to the console 12.

FIGS. 15B and 15C illustrate cross-sectional views of the manifold system 24 taken along lines 15B-15B and lines 15C-15C, respectively. Both FIGS. 15B and 15C show the fluid pick up conduit 62 in operative engagement with the bottle 26 through the seal 267. Suction device(s) is preferably in fluid communication with the fluid pick up conduit 62, and draws fluid out of the bottle 26 through the fluid pick up conduit 62. The fluid can flow through a passageway 161 (see FIG. 15C) extending through the pick up conduit 62. The fluid can flow to and through the lumen 171 towards the line 20. If the switch 29 is off, the fluid from one or more of the upstream bottles can flow along the passage 173. The manifold system 24 then directs the fluid into the line 20.

In certain embodiments, including the embodiment of FIG. 1, the console 12 comprises a computer with display 32. In one embodiment, the display 32 is a user input device comprising a touch screen that controls the computer. In other embodiments, the computer may be controlled by input devices such as a keyboard, keypad, mouse, pointing device, or other input device. The computer controls a variety of functions in the console 12. For example, the computer may control the manifold system 24, and thereby the flow of treatment fluids from the containers 26. In one embodiment, the fluid flowing through the line 20 can be changed by pressing a single button on the touch screen display 32. In another embodiment, the computer contains teaching tutorials that are exhibited on the display 32. In yet another embodiment, the user may change program chips within the computer according to treatment and/or patient. In still another embodiment, the computer records patient and treatment data, for example data gathered during treatment.

The console 12 can also comprise a mechanical system for controlling fluid flow from the containers to the handpiece. One or more pumps, valves, fluid lines, and the like can cooperate to deliver fluid from the containers to the handpiece. The console 12 can be powered pneumatically, electrically, or by any other suitable powering means. The mechanically drive console 12 can have manual controls for controlling fluid flow to the handpiece.

The console 12 can also comprise additional handpieces suitable for other types of skin treatment. These additional handpieces can be used for pre-treatment or post-treatment in combination with other modalities. For example, the console 12 may include a handpiece for diamond tip abrasion, or "crystal-free" microdermabrasion, as described above. Such a handpiece may be useful for more aggressive treatments, in addition to treatment with the handpiece assembly 18. The diamond tips can range from fine to extra coarse.

In some embodiments, the console 12 comprises a handpiece including at least one light emitting diode (LED). Light therapy has been shown to improve skin. For example, red light between about 600 and about 700 nanometers and infrared LED light between about 700 and about 1,000 nanometers reduces the appearance of fine lines and superficial hyperpigmentation. For another example, blue LED light at about 430 nanometers improves the appearance of oily and acne-prone skin. Other benefits of light therapy include promotion of collagen production, increased circulation and moisture retention, smoothing of skin texture, and improvement of skin firmness and resilience.

19

The console 12 can comprise handpieces for vacuum therapy such as lymphatic drainage and cellulite massage. Vacuum therapy enhances the effects of treatment with the handpiece assembly 18 and LED light therapy. Preferably, the vacuum therapy handpieces are sized appropriately for facial massage and body massage. An example of a multi-modality protocol using a plurality of handpieces comprises diamond tip abrasion, treatment with handpiece assembly 18 and at least one treatment fluid from containers 26, vacuum therapy, red light therapy, and application of sunscreen, for example at a minimum skin protection factor (SPF) of 15. The various modalities may be included and ordered by the user depending on the desired outcome of the overall treatment.

The console 12 optionally includes any of a plurality of additional features. For example, a digital camera may be used to take pictures of the patient before and after treatment, and the pictures may be stored on the computer. The computer may hold client medical and treatment records. The computer may be connected to a network. The console 12 may store disks. The console 12 may include an ultrasound unit. The console 12 may include a stimulator, such as an electrical stimulator. The console 12 may include an iontophoresis handpiece. The number of additional features is limitless when considering the range of features that a user may wish to incorporate with the treatment provided by the handpiece assembly 18.

FIG. 16 depicts another embodiment of the skin treatment system 10, which may be generally similar to the embodiment illustrated in FIG. 1, except as further detailed below. Where possible, similar elements are identified with identical reference numerals in the depiction of the embodiment of FIG. 1.

The line 20 includes an output line 50 for removing waste from the handpiece assembly 18 and an input line 52 for delivering treatment material to the handpiece assembly 18. A valve 300 can be disposed along the input line 52 to inhibit backflow of treatment material. The console 12 can pump treatment material through the input line 52 to the handpiece assembly 18 when the handpiece assembly 18 is applied to the person's skin, as detailed above. The fluid flow through the input line 52 can be reduced or stopped so that the handpiece assembly 18 can be removed from the patient's skin. The valve 300 can inhibit the flow of fluid through the input line 52 towards the console 12. A desired amount of treatment material can therefore be contained in the handpiece assembly 18 and the section 310 of the input tubing 52 extending between the valve 300 and the handpiece assembly 18. When the handpiece assembly 18 is applied to a patient's skin, a vacuum can be applied to the output line 50. The vacuum can draw the treatment material out of the handpiece assembly 18 without a substantial or noticeable delay.

In some embodiments, the valve 300 can be a one-way valve, such as a duckbill valve, check valve, or other type of valve for inhibiting fluid flow. In alternative embodiments, the valve 300 can comprise a plurality of valves (e.g., one-way valves, flow regulators, adjustable valves, etc.).

FIG. 17 is a cross-sectional view of the line 20. The input and output lines 50, 52 can have different or similar cross sectional flow areas. The illustrated output line 50 has a passageway 312 with a diameter that is less than the diameter of a passageway 314 of the input line 52. Accordingly, a relatively large slug of treatment material can be stored in the section 310 extending distally from the valve 300 to the handpiece assembly 18. The slug can be quickly

20

delivered out of the handpiece assembly 18 once the handpiece assembly is applied to a patient's skin as detailed above.

In some embodiments, the section 310 of the output line 50 has a length L greater than 6 inches, 12 inches, 18 inches, 24 inches, and ranges encompassing such lengths. In some embodiments, the section 310 of the output line 50 has a length L greater than 24 inches, 30 inches, 36 inches, and ranges encompassing such lengths. The passageway 312 can have a cross-sectional area that is at least 10%, 30%, 50%, 75%, or 100% greater than the cross-sectional area of the passageway 314. The length L and the diameters of the passageways 312, 314 can be selected based on the desired amount of treatment material to be stored in the line 20, delivery and removal rates.

FIGS. 18 and 19 illustrate a modular handpiece assembly 360 having a cartridge 362 containing treatment material. The illustrated handpiece assembly 360 can be used to deliver treatment material from the cartridge 362. The main body 30 can have a pump for pressuring the treatment material. In one embodiment, the fluid control device includes a power supply, such as a battery, which provides power to electrical components (e.g., pumps or valves) of the handpiece assembly 360. The power supply can be a battery that is preferably disposed within the main body 30 of the handpiece assembly 360. In one arrangement, the battery is a rechargeable battery that can be connected to and recharged by an AC power supply, such as a typical residential electrical outlet. Alternatively, the handpiece assembly 360 can be directly powered by an AC power supply. The power supply can provide power to several components of the handpiece assembly 360. For example, the power supply can provide power to a plurality of fluid control devices 330 and/or a flow control unit. A control switch 371 can be used to turn the handpiece assembly 360 Off/On and/or control the output of the handpiece assembly 360.

In operation, the cartridge 362 can be inserted into the main body 30. The handpiece assembly 360 can be applied to a patient's skin to deliver treatment material from the cartridge 362 to the patient's skin. After delivering a desired amount of treatment material, the cartridge 362 can be separated from the main body 30. The cartridge 362 can be a one-use or multi-use cartridge. For example, the cartridge can be a non-refillable disposable cartridge.

The tip 34 can also be used to remove hair or perform other skin treatments. For example, the tip 34 can include one or more razor blades and may be configured to apply a treatment material (e.g., antioxidants, vitamins, serums, growth agents, etc.) to the skin during the shaving process. In such embodiments, the main body 30 can be an elongated handle that is connected to a transversely extending elongate tip 34. In some embodiments, the handpiece assembly can be in the form of a disposable handheld razor. The treatment material can reduce or substantially eliminate problems associated with wet or dry shaving systems. These treatment materials may be applied prior to, during, before, and/or after shaving.

The articles disclosed herein may be formed through any suitable means. The various methods and techniques described above provide a number of ways to carry out the invention. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods may be performed in a manner that achieves or optimizes one advantage or group of

21

advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.

Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments disclosed herein. Similarly, the various features and steps discussed above, as well as other known equivalents for each such feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Additionally, the methods which are described and illustrated herein are not limited to the exact sequence of acts described, nor are they necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the embodiments of the invention.

Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

What is claimed is:

1. A skin treatment system, comprising:

a console configured to receive a first container containing a first treatment material and a second container containing a second treatment material;

a handpiece configured to couple to a tip that can be pressed against skin to perform skin treatment; a supply line connected between the handpiece and the console for sequentially delivering treatment material to the handpiece from the first container or the second container;

a waste line connected between the handpiece and the console; and

a vacuum source configured to create a vacuum that draws waste material from the handpiece through the waste line for disposal and that draws treatment material from either the first container or the second container to the handpiece when the tip is pressed against skin.

2. The system of claim 1, further comprising:

a flow rate controller to adjust a flow rate of the first treatment material or the second treatment material to the handpiece, wherein the flow rate controller is located on the handpiece or on the console; and

a user input device to select the first treatment material or the second treatment material for delivery to the handpiece.

3. The system of claim 1, further comprising a flow rate controller to adjust a flow rate of the first treatment material or the second treatment material to the handpiece.

4. The system of claim 3, wherein the flow rate controller is located on the handpiece.

5. The system of claim 3, wherein the flow rate controller is located on the console.

6. The system of claim 1, further comprising a computing device configured to control at least one function of the system.

7. The system of claim 1, further comprising a user input device to select the first treatment material or the second treatment material for delivery to the handpiece.

8. The system of claim 7, wherein the user input device comprises a touch screen.

9. The system of claim 7, wherein the user input device is positioned on the console.

22

10. The system of claim 1, wherein the console comprises a display.

11. A skin treatment system, comprising:

a console configured to receive a first container containing a first treatment material and a second container containing a second treatment material;

a handpiece configured to couple to a tip that can be placed against skin to perform skin treatment;

a supply line extending between the handpiece and the console for sequentially delivering treatment material to the handpiece from the first container or the second container;

a waste line extending between the handpiece and the console;

a vacuum source configured to create a vacuum that draws waste material from the handpiece through the waste line for disposal and that draws treatment material from either the first container or the second container to the handpiece when the tip is placed against skin; and

a computing device configured to control at least one function of the system.

12. The system of claim 11, further comprising:

a flow rate controller to adjust a flow rate of the first treatment material or the second treatment material to the handpiece, wherein the flow rate controller is located on the handpiece or on the console; and

a user input device to select the first treatment material or the second treatment material for delivery to the handpiece.

13. The system of claim 11, further comprising a flow rate controller to adjust a flow rate of the first treatment material or the second treatment material to the handpiece.

14. The system of claim 13, wherein the flow rate controller is located on the handpiece.

15. The system of claim 13, wherein the flow rate controller is located on the console.

16. The system of claim 11, further comprising a user input device to select the first treatment material or the second treatment material for delivery to the handpiece.

17. The system of claim 16, wherein the user input device comprises a touch screen.

18. The system of claim 16, wherein the user input device is positioned on the console.

19. The system of claim 11, wherein the console comprises a display.

20. A skin treatment system, comprising:

a console configured to receive a first container containing a first treatment material and a second container containing a second treatment material;

a handpiece configured to couple to a tip that can be pressed against skin to perform skin treatment;

a supply line connected between the handpiece and the console for sequentially delivering treatment material to the handpiece from the first container or the second container;

a waste line connected between the handpiece and the console;

a vacuum source configured to create a vacuum that draws waste material from the handpiece through the waste line for disposal and that draws treatment material from either the first container or the second container to the handpiece when the tip is pressed against skin;

23

a flow rate controller to adjust a flow rate of the first treatment material or the second treatment material to the handpiece, wherein the flow rate controller is located on the handpiece or on the console; and
a user input device to select the first treatment material or the second treatment material for delivery to the handpiece.

* * * * *

24